HTG Molecular Diagnostics (HTGMQ) 10-K 29 Mar 22 2021 FY Annual report Financial data

Document and Entity Information

Document and Entity Information - USD ($)	12 Months Ended
	Dec. 31, 2021	Mar. 15, 2022	Jun. 30, 2021
Cover [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2021
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	FY
Trading Symbol	HTGM
Entity Registrant Name	HTG Molecular Diagnostics, Inc
Entity Central Index Key	0001169987
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Non-accelerated Filer
Entity Shell Company	false
Entity Small Business	true
Entity Emerging Growth Company	false
Entity File Number	001-37369
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	86-0912294
Entity Address, Address Line One	3430 E. Global Loop
Entity Address, City or Town	Tucson
Entity Address, State or Province	AZ
Entity Address, Postal Zip Code	85706
City Area Code	(877)
Local Phone Number	289-2615
Document Annual Report	true
Document Transition Report	false
Entity Interactive Data Current	Yes
ICFR Auditor Attestation Flag	false
Entity Common Stock, Shares Outstanding		7,590,733
Entity Public Float			$ 42,885,725
Title of 12(b) Security	Common Stock, par value $0.001 per share
Security Exchange Name	NASDAQ
Auditor Name	BDO USA, LLP
Auditor Location	Los Angeles, California
Auditor Firm ID	243

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Current assets:
Cash and cash equivalents	$ 9,599,950	$ 22,397,812
Short-term investments available-for-sale, at fair value	12,343,456	6,298,075
Accounts receivable, net of allowance of $20,315 at December 31, 2021 and $0 at December 31, 2020	2,092,466	1,588,767
Inventory, net of allowance of $25,306 at December 31, 2021 and $26,052 at December 31, 2020 – current	1,987,753	1,492,126
Prepaid expenses and other	1,163,339	1,094,273
Total current assets	27,186,964	32,871,053
Operating lease right-of-use assets	1,345,361	1,009,097
Property and equipment, net	1,118,886	1,227,402
Other non-current assets	809,476	90,356
Total assets	30,460,687	35,197,908
Current liabilities:
Accounts payable	1,649,440	1,348,762
Accrued liabilities	2,022,569	1,459,878
Contract liabilities – current	124,941	185,083
NuvoGen obligation – current	548,301	512,729
Current portion of long-term debt	5,167,586	3,022,139
Operating lease liabilities – current	413,865	685,220
Other current liabilities	16,808	22,563
Total current liabilities	9,943,510	7,236,374
NuvoGen obligation - non-current, net of discount	3,900,880	4,479,396
Long-term debt, net of current portion, discount and debt issuance costs	5,178,629	8,568,308
Operating lease liabilities - non-current	949,461	368,682
Other non-current liabilities	88,383	60,488
Total liabilities	20,060,863	20,713,248
Commitments and Contingencies (Note 15)
Stockholders’ equity:
Series A convertible preferred stock, $0.001 par value; 23,770 shares authorized, issued and outstanding at December 31, 2021 and 2020	24	24
Common stock, $0.001 par value; 26,666,667 shares authorized at December 31, 2021 and 2020, 7,588,085 shares issued and outstanding at December 31, 2021 and 5,199,997 shares issued and outstanding at December 31, 2020	7,588	5,200
Additional paid-in-capital	218,723,349	205,661,999
Accumulated other comprehensive income	1,894	5,298
Accumulated deficit	(208,333,031)	(191,187,861)
Total stockholders’ equity	10,399,824	14,484,660
Total liabilities and stockholders' equity	$ 30,460,687	$ 35,197,908

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Accounts receivable net allowance	$ 20,315	$ 0
Inventory net allowance	$ 25,306	$ 26,052
Preferred stock, par value	$ 0.001
Preferred stock, shares authorized	10,000,000
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	26,666,667	26,666,667
Common stock, shares issued	7,588,085	5,199,997
Common stock, shares outstanding	7,588,085	5,199,997
Series A Convertible Preferred Stock
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	23,770	23,770
Preferred stock, shares issued	23,770	23,770
Preferred stock, shares outstanding	23,770	23,770

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Revenue:
Total revenue	$ 8,906,828	$ 8,548,864
Operating expenses:
Cost of product and product-related services revenue	$ 4,094,980	$ 3,991,532
Cost, Product and Service [Extensible Enumeration]	us-gaap:ProductAndServiceOtherMember	us-gaap:ProductAndServiceOtherMember
Selling, general and administrative	$ 16,546,740	$ 18,063,064
Research and development	6,088,934	6,079,907
Total operating expenses	26,730,654	28,134,503
Operating loss	(17,823,826)	(19,585,639)
Other income (expense):
Interest expense	(1,064,545)	(1,024,774)
Interest income	29,884	254,736
Other income		22,268
Gain on forgiveness of PPP Loan	1,735,792
Loss on extinguishment of MidCap Credit Facility and QNAH Convertible Note		(522,394)
Total other income (expense)	701,131	(1,270,164)
Net loss before income taxes	(17,122,695)	(20,855,803)
Provision for income taxes	(22,475)	(14,415)
Net loss	$ (17,145,170)	$ (20,870,218)
Net loss per share, basic and diluted	$ (2.47)	$ (4.51)
Shares used in computing net loss per share, basic and diluted	6,936,131	4,627,918
Product and Product-related Services
Revenue:
Total revenue	$ 8,906,828	$ 7,890,854
Collaborative Development Services
Revenue:
Total revenue		$ 658,010

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Loss - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement Of Income And Comprehensive Income [Abstract]
Net loss	$ (17,145,170)	$ (20,870,218)
Other comprehensive income (loss), net of tax effect:
Unrealized gain on short-term investments		9
Foreign currency translation adjustment	(3,404)	10,253
Total other comprehensive income (loss)	(3,404)	10,262
Comprehensive loss	$ (17,148,574)	$ (20,859,956)

Consolidated Statements of Chan

Consolidated Statements of Changes in Stockholders' Equity - USD ($)	Total	L P Purchase Agreement	ATM Offering	Private Placement	Series A Convertible Preferred Stock	Series A Convertible Preferred StockPrivate Placement	Common Stock	Common StockL P Purchase Agreement	Common StockATM Offering	Additional Paid-In Capital	Additional Paid-In CapitalL P Purchase Agreement	Additional Paid-In CapitalATM Offering	Additional Paid-In CapitalPrivate Placement	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit
Balance at Dec. 31, 2019	$ 23,969,634						$ 3,873			$ 194,288,368				$ (4,964)	$ (170,317,643)
Balance, shares at Dec. 31, 2019							3,872,682
Stock-based compensation expense	1,584,666									1,584,666
Release of restricted stock awards	119						$ 8			111
Release of restricted stock awards, shares							7,911
Net share settlement of restricted stock awards	(14,049)						$ (2)			(14,047)
Net share settlement of restricted stock award, shares							(1,764)
Stock issued under stock purchase plans	$ 62,162						$ 6			62,156
Stock issued under stock purchase plans, shares	0						6,286
Issuance of common stock			$ 7,545,838						$ 955			$ 7,544,883
Issuance of common stock, shares									955,240
Issuance of preferred stock	$ 2,424,900			$ 562,955	$ 41	$ 10				2,424,859			$ 562,945
Issuance of preferred stock, shares					41,100	10,170
Cancellation of common stock received in exchange for Series A convertible preferred stock	(2,424,900)						$ (274)			(2,424,626)
Cancellation of common stock received in exchange for Series A convertible preferred stock, shares							(274,000)
Conversion of Series A convertible preferred stock for common stock					$ (27)		$ 183			(156)
Conversion of Series A convertible preferred stock for common stock, shares					(27,500)		183,333
Shares issued, including stock compensation expense		$ 1,182,083						$ 239			$ 1,181,844
Shares issued, including stock compensation expense, shares								238,658
Exercise of pre-funded warrants	31,768						$ 212			31,556
Exercise of pre-funded warrants, shares							211,784
Issuance of common stock warrants in connection with SVB Term Loan	420,000									420,000
Cash in lieu of fractional shares related to reverse stock split	(560)									(560)
Cash in lieu of fractional shares related to reverse stock split, shares							(133)
Net loss	(20,870,218)														(20,870,218)
Unrealized gain on short-term investments	9													9
Foreign currency translation adjustment	10,253													10,253
Balance at Dec. 31, 2020	14,484,660				$ 24		$ 5,200			205,661,999				5,298	(191,187,861)
Balance, shares at Dec. 31, 2020					23,770		5,199,997
Stock-based compensation expense	1,317,351									1,317,351
Release of restricted stock awards	4						$ 4
Release of restricted stock awards, shares							4,529
Net share settlement of restricted stock awards	(3,239)									(3,239)
Net share settlement of restricted stock award, shares							(611)
Employee stock purchase plan expense	57,669									57,669
Stock issued under stock purchase plans	$ 125,828						$ 34			125,794
Stock issued under stock purchase plans, shares	0						33,963
Issuance of common stock		$ 899,980	$ 10,665,819					$ 154	$ 2,051		$ 899,826	$ 10,663,768
Issuance of common stock, shares								154,372	2,050,879
Conversion of Series A convertible preferred stock for common stock, shares							144,881
Exercise of pre-funded warrants							$ 145			(145)
Exercise of pre-funded warrants, shares							144,881
Net loss	$ (17,145,170)														(17,145,170)
Exercise of stock options	326									326
Exercise of stock options, shares							75
Foreign currency translation adjustment	(3,404)													(3,404)
Balance at Dec. 31, 2021	$ 10,399,824				$ 24		$ 7,588			$ 218,723,349				$ 1,894	$ (208,333,031)
Balance, shares at Dec. 31, 2021					23,770		7,588,085

Consolidated Statements of Ch_2

Consolidated Statements of Changes in Stockholders' Equity (Parenthetical) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Statement Of Stockholders Equity [Abstract]
At the market offering, commissions and issuance costs	$ 300,000	$ 300,000
Private placement issuance costs		$ 37,000

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Operating activities
Net loss	$ (17,145,170)	$ (20,870,218)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	721,246	1,346,560
Accretion of discount on NuvoGen obligation	(12,288)	(12,936)
Provision for excess inventory	174,589	53,298
Amortization of QNAH Convertible Note issuance costs		6,505
Amortization of MidCap Credit Facility discount and issuance costs		101,482
Amortization of SVB Term Loan discount and issuance costs	470,281	243,541
Stock-based compensation expense	1,317,355	1,584,785
Employee stock purchase plan expense	57,669	21,186
Bad debt expense	20,315
Non-cash operating lease expense	458,001	629,501
Accrued interest on available-for-sale securities investments	(25,018)	(72,503)
Stock compensation expense in connection with LP Purchase Agreement		205,538
Gain on forgiveness of PPP Loan	(1,735,792)
Loss on extinguishment of Midcap Credit Facility and QNAH Convertible Note		522,394
Loss on abandonment and disposal of assets, net	180,008	105,063
Changes in operating assets and liabilities:
Accounts receivable	(805,736)	1,575,409
Inventory	(1,365,384)	(256,940)
Prepaid expenses and other	619,226	284,921
Deferred offering costs		140,320
Accounts payable	453,337	(23,801)
Accrued liabilities	616,447	(409,035)
Contract liabilities	(38,314)	(683,716)
Operating lease liabilities	(469,326)	(783,731)
Net cash used in operating activities	(16,508,554)	(16,292,377)
Investing activities
Purchase of property and equipment	(644,381)	(453,552)
Maturities of available-for-sale securities	12,600,000	31,650,000
Purchase of available-for-sale securities	(18,620,363)	(12,465,341)
Net cash (used in) provided by investing activities	(6,664,744)	18,731,107
Financing activities
Proceeds from issuance of SVB Term Loan		10,000,000
Payment of SVB Term Loan issuance costs		(115,193)
Proceeds from ATM Offering, net of commissions of $0.3 million	10,665,819	7,545,838
Proceeds from LP Purchase Agreement	899,980	976,545
Proceeds from PPP Loan		1,717,000
Proceeds from Series A convertible preferred stock in private placement		562,955
Payments on NuvoGen obligation	(530,656)	(645,949)
Proceeds from exercise of pre-funded warrants		31,768
Payments on financing leases	(22,563)	(41,134)
Proceeds from exercise of stock options	326
Taxes paid for net share settlement of restricted stock awards	(3,239)	(14,049)
Cash in lieu of fractional shares related to reverse stock split		(560)
Proceeds from shares purchased under stock purchase plans	125,828	40,976
Payments on 2021 and 2020 Insurance Notes	(743,873)	(570,096)
Net cash provided by financing activities	10,391,622	9,049,478
Effect of exchange rates on cash	(16,186)	19,609
Increase (decrease) in cash, cash equivalents and restricted cash	(12,797,862)	11,507,817
Cash, cash equivalents and restricted cash at beginning of year	22,397,812	10,889,995
Cash and cash equivalents at end of year	9,599,950	22,397,812
Supplemental disclosure of noncash investing and financing activities
Issuance of Series A convertible preferred stock in exchange for outstanding common stock		2,424,900
Issuance of common stock upon conversion of Series A convertible preferred stock		1,622,500
Issuance of common stock warrants in connection with SVB Term Loan		420,000
Issuance of common stock from cashless exercise of pre-funded warrants	145
Operating lease right-of-use assets obtained in exchange for operating lease liabilities	1,302,457	447,987
Carrying value of demonstration units transferred from property and equipment to inventory	16,128	18,817
2021 and 2020 Insurance Notes issued for insurance premiums	746,360	735,195
Reclassification of contract liability to refund liability		281,722
Disposal of fully depreciated assets	635,870
Gain on forgiveness of PPP Loan	1,735,792
Supplemental cash flow information
Cash paid for interest	599,922	869,857
Cash paid for taxes	$ 12,665	17,514
QNAH Convertible Note
Financing activities
Payments for extinguishment of debt		(3,000,000)
MidCap Credit Facility
Financing activities
Payments for extinguishment of debt		$ (7,438,623)

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) $ in Millions	12 Months Ended
	Dec. 31, 2021USD ($)
ATM Offering
Subsidiary Sale Of Stock [Line Items]
Underwriting discounts, commissions and issuance costs	$ 0.3

Description of Business, Basis

Description of Business, Basis of Presentation and Principles of Consolidation	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Description of Business, Basis of Presentation and Principles of Consolidation	Note 1. Description of Business, Basis of Presentation and Principles of Consolidation HTG Molecular Diagnostics, Inc. (the “Company”) is a life science company whose mission is to advance precision medicine through its innovative transcriptome-wide profiling technology. The Company derives revenue from sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (“NGS-based”) HTG EdgeSeq assays, from sample processing services performed in its VERI/O laboratory and from collaborative development services. The Company operates in one segment and its customers and distributors are geographically located primarily in the United States and Europe. For sales to distributors, their locations may be different from the locations of the end customers. For the year ended December 31, 2021, approximately 31% of the Company’s revenue was generated from sales originated by customers located outside of the United States, compared with 35% for the year ended December 31, 2020. COVID-19 Pandemic The full impact of the COVID-19 pandemic continues to evolve as of the date of this report and management continues to actively monitor the potential impact of the global situation on its financial condition, liquidity, operations, suppliers, industry and workforce. Given the ongoing evolution of the COVID-19 pandemic, including resurgences in many areas of the world and the global responses to curb its spread, the Company is not able to fully estimate the effects of the COVID-19 pandemic on its results of operations, financial condition or liquidity. The Company experienced a significant slowing of product and product-related services revenue generation beginning in March 2020 and believes that while it has seen some recovery, this impact will continue to be seen at some level at least through the first half of 2022. The extent of this impact varied from customer to customer depending upon how they have been directly or indirectly impacted by local stay-at-home orders and other social distancing measures, prioritization by those customers as the immediate impacts of the pandemic have passed, and the workforce and supplier impacts that each customer has experienced during the pandemic. The Company has not experienced delays in its development efforts because of stay-at-home orders despite its efforts to prioritize the safety of its employees during this pandemic. In addition, the impact of the COVID-19 pandemic on the Company’s ability to source raw materials and other supplies has not been significant to date. However, a change in or loss of suppliers or other supply chain or distribution network partners due to the ongoing impacts of the pandemic on the global economy could adversely affect the Company’s business and the businesses of its vendors, partners and customers, and could result in future reductions in sales and operating results. While there remains uncertainty as to the ultimate impact of the COVID-19 pandemic, the Company has considered the known impacts on its business as of the date these consolidated financial statements were issued and has reflected any known or expected impacts in its consolidated financial statements, including consideration of potential impairment risks to its long-lived assets, potential accounts receivable collection risks and potential impacts to its overall liquidity position. Basis of Presentation The consolidated financial statements and accompanying notes were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In November 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen shares of issued and outstanding common stock were exchanged for one share of common stock. All share and per share amounts within the consolidated financial statements and notes thereto have been adjusted to reflect the reverse stock split for all periods and dates presented. See Note 14 for more information about the Company’s reverse stock split. Principles of Consolidation The Company formed a French subsidiary, HTG Molecular Diagnostics France SARL, in November 2018. The consolidated financial statements include the accounts of the Company and this wholly owned subsidiary after elimination of intercompany transactions and balances as of December 31, 2021 and 2020. Going Concern and Management has assessed the Company’s ability to continue as a going concern within one year of issuance of these consolidated financial statements. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of the assets and satisfaction of liabilities in the normal course of business. However, the Company has had recurring operating losses and negative operating cash flows since its inception and has an accumulated deficit of $208.3 million as of December 31, 2021. As of December 31, 2021, the Company had working capital of $17.2 million and long-term liabilities of $10.1 million. The Company’s liability balances consist primarily of its debt obligations, including an asset-secured loan with Silicon Valley Bank (“SVB”) (the “SVB Term Loan”) (see Note 8), as well as an obligation to NuvoGen Research, LLC (the “NuvoGen obligation”) (see Note 10). Potentially changing circumstances, including COVID-19 uncertainties, may result in the depletion of the Company’s capital resources more rapidly than it currently anticipates, resulting in the Company not having adequate resources to fund its planned operations and expenditures for at least the next 12 months and to comply with the financial covenant in the Loan and Security Agreement for the SVB Term Loan (the “Loan Agreement”). These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties. The Company will need to raise additional capital to fund its operations and service its long-term debt obligations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. In addition, the Company must comply with a financial covenant in the Loan Agreement requiring the Company to maintain unrestricted cash, including short term available-for-sale securities, of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2. Summary of Significant Accounting Policies Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s estimates include revenue recognition, stock-based compensation expense, bonus and warranty accrual, income tax valuation allowances and reserves, recovery of long‑lived assets, lease liability, inventory obsolescence and valuation of inventory, accounts receivable, allowance for doubtful accounts and available-for-sale securities. Actual results could materially differ from those estimates, especially in light of the significant uncertainty that remains as to the full impact of COVID-19 on the Company’s operations, as well as those of its workforce, supply chains, distribution networks and those of its customers. Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with financial institutions, commercial paper, money market instruments and high credit quality corporate debt securities purchased with a term of three months or less. Accounts Receivable Accounts receivable represent valid claims against debtors. Management reviews accounts receivable regularly to determine, using the specific identification method, if any receivable amounts will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value. Investments in Available-for-Sale Securities The Company classifies its debt securities, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive loss, net of tax, as available-for-sale securities. Investments in securities with maturities of less than one year, or where management’s intent is to use the investments to fund current operations, or to make them available for current operations, are classified as short-term investments. Realized gains, realized losses and declines in value of securities judged to be other-than-temporary, are included in other income (expense) within the consolidated statements of operations. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Interest earned on securities is also included in other income (expense) within the consolidated statements of operations. The Company recognizes other-than-temporary impairment (“OTTI”) of a debt security for which there has been a decline in fair value below amortized cost if (i) management intends to sell the security, (ii) it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, or (iii) the Company does not expect to recover the entire amortized cost basis of the security. The amount by which amortized cost exceeds the fair value of a debt security that is considered to have OTTI is separated into a component representing the credit loss, which is recognized in earnings, and a component related to all other factors, which is recognized in other comprehensive income (loss). The measurement of the credit loss component is equal to the difference between the debt security’s amortized cost basis and the present value of its expected future cash flows discounted at the security’s effective yield. If the Company intends to sell the security, or if it is more likely than not it will be required to sell the security before recovery, an OTTI write-down is recognized in earnings equal to the entire difference between the amortized cost basis and fair value of the security . Fair Value of Financial Instruments Fair value measurements are based on the premise that fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the inputs used in measuring fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities on the reporting date. Level 2 – Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management’s judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. The fair values are therefore determined using factors that involve considerable judgment and interpretations, including but not limited to private and public comparables, third-party appraisals, discounted cash flow models, and fund manager estimates. The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which is determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. The carrying value of the SVB Term Loan (see Note 8) is estimated to approximate its fair value as the interest rate approximates the market rate for debt with similar terms and risk characteristics. The NuvoGen obligation relates to an asset purchase transaction with a then-common stockholder of the Company (see Note 10). As of December 31, 2021, the estimated aggregate fair value of the NuvoGen obligation is approximately $4.6 million, determined using a Monte Carlo simulation with key assumptions including future revenue, volatility, discount and risk-free rates. The estimated fair value of the NuvoGen obligation represents a Level 3 measurement. Inventory Inventory, consisting of raw materials, work in process and finished goods, is stated at the lower of cost (first-in, first-out) or net realizable value. Cost is determined using a standard cost system, whereby the standard costs are updated periodically to reflect current costs. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion and disposal. The Company reserves or writes down its inventory for estimated obsolescence or inventory in excess of reasonably expected near term sales or unmarketable inventory, in an amount equal to the difference between the cost of inventory and the estimated market value, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. The Company classifies inventory as long-term when the Company expects to utilize the inventory beyond its normal operating cycle. Equipment that is under evaluation for purchase remains in inventory as the Company maintains title to the equipment throughout the evaluation period. The period of time customers use to evaluate the Company’s equipment generally ranges from 90 to 180 days, and in certain circumstances the evaluation period may need to be extended beyond that period. However, in no case will the evaluation period exceed one year. If the customer has not purchased the equipment or entered into a reagent rental agreement with the Company after evaluating the product for one year, the equipment is returned to the Company or the customer is allowed to continue use of the equipment, in which case the equipment is written off to selling, general and administrative expense in the consolidated statements of operations. HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Finished goods inventory under evaluation as of December 31, 2021 was $204,638 compared with $50,855 as of December 31, 2020. Property and Equipment Property and equipment are stated at historical cost and depreciated over their useful lives, which range from three to five years, using the straight-line method. Equipment used in the field is amortized using the straight-line method over the lesser of the period of the related reagent rental or collaborative development services agreement where applicable or the estimated useful life. Leasehold improvements are amortized using the straight-line method over the lesser of the remaining lease term or the estimated useful life. Costs incurred in the development and installation of software for internal use and in the development of the Company’s website are expensed or capitalized, depending on whether they are incurred in the preliminary project stage (expensed), application development stage (capitalized), or post-implementation stage (expensed). Amounts capitalized following project completion are amortized on a straight-line basis over the useful life of the developed asset, which is generally three years. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to the estimated undiscounted future cash flows expected to be generated by the asset group. If the carrying amount of an asset group exceeds its estimated future cash flow, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Although the Company has accumulated losses since inception, the Company believes the future cash flows will be sufficient to exceed the carrying value of the Company’s long-lived assets. There were no impairments of long-lived assets during the years ended December 31, 2021 and 2020. Leases Arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheets as both a right-of-use asset and a lease liability for each type of lease, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For financing leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded to rent expense as incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components for all classes of assets currently under lease, including facilities and computer equipment. The Company excludes short-term leases having initial terms of 12 months or less as an accounting policy election and recognizes rent expense on short-term leases on a straight-line basis over the lease term for these leases. Debt Issuance Costs and Debt Discounts Costs incurred to issue non-revolving debt instruments are recognized as a reduction to the related debt balance in the consolidated balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Costs incurred to issue the Loan Agreement with SVB were deferred as an asset in the consolidated balance sheets and are being amortized on a straight-line basis to interest expense over the term of the loan. Cost incurred to issue the MidCap Credit and Security Agreement (Revolving Loan) under the Company’s credit facility with MidCap Financial Trust (the “MidCap Credit Facility”) were deferred as an asset in the consolidated balance sheets and amortized on a straight-line basis to interest expense over the term of the revolving commitment until extinguishment of the MidCap Credit Facility in June 2020 (see Note 8) . Contract Liabilities Contract liabilities represent cash receipts for products or services to be delivered in future periods, including up-front fees received relating to custom research use only (“RUO”) assay design and collaborative development services. When products or services are delivered to customers, contract liabilities are recognized as earned. Up-front fees received for custom RUO assay design or collaborative development services are recognized over time based on the costs incurred to date compared with total expected costs as design or development procedures are completed and outputs are produced. Revenue Recognition The Company accounts for its revenue in accordance with Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers Collaborative Arrangements For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. The Company has made a policy election to exclude from the measurement of the transaction price all taxes assessed by a government authority that are both imposed on and concurrent with a specific revenue producing transaction and collected by the Company from a customer. Such taxes may include but are not limited to sales, use, value added and certain excise taxes. See Note 9 for additional discussion of the Company’s revenue recognition policies. COVID-19 Related Credits and Relief In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to COVID‑19. On April 21, 2020, the Company received proceeds from a loan pursuant to the Paycheck Protection Program (“PPP”) of the CARES Act (the “PPP Loan”) in the amount of $1.7 million from SVB, as lender (see Note 8). There is no guidance in U.S. GAAP that specifically addresses the accounting by a business entity that obtains a forgivable loan from a government entity. Notwithstanding the absence of specific guidance in U.S. GAAP and given the significant uncertainties related to whether many entities that received loans are qualified for a PPP Loan and would meet the conditions for loan forgiveness, the Company accounted for the PPP Loan as debt in accordance with FASB, ASC 470, Debt In December 2020, the Consolidated Appropriations Act (the “Appropriations Act”) was signed into law to further address the ongoing impacts of COVID-19. The Appropriations Act introduced several additional potential credits and benefits for employers to consider applying for, including, but not limited to, the ability for employers who have previously obtained a PPP Loan to potentially also qualify for Employee Retention Credits (“ERC”), initially created as part of the CARES Act. The ERC provided a per employee credit to eligible businesses based on a percentage of qualified wages and health insurance benefits paid to employees. The benefit was provided as a refundable payroll tax credit claimed quarterly as a reduction to payroll taxes or cash refunds. The initial credit available was equal to 50% of qualified wages paid to employees during a quarter, capped at $10,000 of qualified wages per employee through December 31, 2021. In March 2021, the American Rescue Plan of 2021 was enacted to, amongst other things, extend and expand ERC benefits through December 31, 2021. In accordance with these additional relief provisions, the tax credit was increased to 70% of qualified wages paid to employees during a quarter, and the limit on qualified wages per employee was increased to $10,000 of qualified wages per quarter. In November 2021, the Infrastructure Investment and Jobs Act was signed into law and ends the employee retention credit early, making wages paid after September 30, 2021, ineligible for the credit. The Company qualified for certain ERC benefits during the years ended December 31, 2021 and 2020. As there is no guidance in U.S. GAAP that specifically addresses the accounting for the receipt of government assistance similar to the ERC, the Company considered two primary approaches in accounting for the ERC. The first was as government grants, by reference to ASC 958-605, Not-for-Profit-Entities Revenue Recognition, and the other by reference to IAS 20, Accounting for Government Grants and Disclosure of Government Assistance. With reference to IAS 20, the Company considered the following: (1) Under this model, the Company would not recognize government assistance until reasonably sure any conditions attached to the assistance would be met, and the Company would in fact receive the funds. (2) Once the Company was reasonably certain the conditions were met, the Company would then record the earnings impact of the grants over the periods in which the Company recognizes the costs the grants are intended to pay for. These costs should be recognized as expenses. (3) The funds could be recorded as other income or as an offset to related qualifying expenses. The Company has historically offset actual expenses that are reimbursed within the applicable expense line. Because the ERC was intended to reimburse the Company for actual costs incurred during the given period or quarter, the Company determined that it was most reasonable to account for these credits as an offset to the qualifying payroll expenses. ERC benefits of approximately $1.7 million and $0.5 million were included in operating expenses as an offset to the related compensation costs in the accompanying consolidated statements of operations for the years ended December 31, 2021 and 2020, respectively, as follows: Years Ended December 31, 2021 2020 Cost of product and product-related services revenue $ 467,481 $ 108,714 Selling, general and administrative 795,650 229,025 Research and development 444,888 135,744 $ 1,708,019 $ 473,483 ERC benefits receivable of $0.4 million and $0.5 million were included in prepaid expenses and other in the accompanying consolidated balance sheets as of December 31, 2021 and 2020, respectively. The Company has also applied the guidance in ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance Laws and regulations concerning government programs, including the ERC and PPP Loan, are complex and subject to varying interpretations. Claims made under these programs may also be subject to retroactive audit and review. While we do not believe there is a basis for estimation of an audit or recapture risk at this time, there can be no assurance that regulatory authorities will not challenge the Company’s claim to the ERC or PPP Loan in a future period. Product Warranty The Company generally provides a one-year warranty on its HTG EdgeSeq platform covering the performance of system hardware and software in conformance with customer specifications under normal use and protecting against defects in materials and workmanship. The Company may, at its option, replace, repair or exchange products covered under valid warranty claims. A provision for estimated warranty costs is recognized at the time of sale, through cost of product and product-related services revenue, based upon recent historical experience and other relevant information as it becomes available. Customers have the option to purchase an extended warranty after the one-year warranty period expires. The Company continuously assesses the adequacy of its product warranty accrual by reviewing actual claims and adjusts the provision as needed. Warranty accrual is included in accrued liabilities and other non-current liabilities in the consolidated balance sheets. Research and Development Expenses Research and development expenses represent costs incurred internally for and externally in support of research and development activities. These costs include those generated through research and development efforts for the improvement and expansion of the Company’s proprietary technology and product offerings, including the technology related to the Company’s HTG Therapeutics business units, costs to continue improving and expanding the utility of the HTG EdgeSeq technology, as well as those related to third-party collaborative development agreements, for which related revenue is included in collaborative development services revenue in the consolidated statements of operations. There were no costs associated with collaborative development services included in research and development expense in the consolidated statements of operations for the year ended December 31, 2021. Stock-based Compensation The Company incurs stock-based compensation expense relating to grants of restricted stock units (“RSUs”) and stock options to employees, consultants and non-employee directors under its equity incentive plans, and stock purchase rights granted under its employee stock purchase plans. The Company recognizes expense for stock-based awards based on the fair value of awards on the date of grant. The fair value of RSUs is based on the quoted market price of the Company’s common stock on the date of grant. The fair value of stock purchase rights and stock options granted pursuant to the Company’s equity incentive plans is estimated on the date of grant using the Black-Scholes option pricing model. The determination of the fair value utilizing the Black-Scholes option pricing model is affected by the fair value of the Company’s stock price and several assumptions, including volatility, expected term, risk-free interest rate, and dividend yield. Generally, these assumptions are based on historical information and judgment is required to determine if historical trends may be indicators of future outcomes. The Company accounts for forfeitures as they occur. Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts and tax base of assets and liabilities using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established against net deferred tax assets for the uncertainty it presents of our ability to use the net deferred tax assets, in this case, primarily carryforwards of net operating tax losses and research and development tax credits. In assessing the realizability of net deferred tax assets we have assessed the likelihood that net deferred tax assets will be recovered from future taxable income, and to the extent that it is “more likely than not” that the assets will not be recovered or there is an insufficient history of operating profits, a valuation allowance is established. We record the valuation allowance in the period we determine that it is more likely than not that net deferred tax assets will not be realized. For the years ended December 31, 2021 and 2020, we have provided a full valuation allowance for all net deferred tax assets due to their current realization being considered remote in the near term. Uncertain tax positions taken or expected to be taken in a tax return are accounted for using the more likely than not threshold for financial statement recognition and measurement. Therefore, for income tax positions where it is not more likely than not that a tax benefit will be sustained in a court of last resort, the Company does not recognize a tax benefit in its financial statements. Foreign Currency Translation and Foreign Currency Transactions The Company has assets and liabilities, including accounts receivable and accounts payable, which are denominated in currencies other than its functional currency. These assets and liabilities are subject to re-measurement, the impact of which is recorded in selling, general and administrative expense within the consolidated statements of operations. Adjustments resulting from translating foreign functional currency financial statements of the Company’s wholly owned subsidiary into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in the consolidated statements of changes in stockholder’s equity. Comprehensive Income (Loss) Comprehensive income (loss) includes certain changes in equity that are excluded from net loss. Specifically, unrealized gains and losses on short-term available-for-sale investments and adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in comprehensive loss. Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom RUO assay design and collaborative development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company’s top two customers accounted for 20% and 10% of the Company’s total revenue for the year ended December 31, 2021, compared with the top customer accounting for 11% of the Company’s total revenue for the year ended December 31, 2020. The largest two customers accounted for approximately 18% and 17% of the Company’s accounts receivable as of December 31, 2021. The third and fourth largest customers accounted for approximately 10% each of the Company’s accounts receivable as of December 31, 2021. The largest two customers accounted for approximately 9% each of the Company’s accounts receivable as of December 31, 2020. Two vendors accounted for 28% and 16% of the Company’s accounts payable as of December 31, 2021, compared with two vendors who accounted for 21% and 20% of the Company’s accounts payable as of December 31, 2020. The Company is also subject to supply chain risks related to the reliance on a single supplier to manufacture a subcomponent used in its HTG EdgeSeq instruments. Although there are a limited number of manufacturers for components of this type, the Company believes that other suppliers could provide similar products on comparable terms. However, a change in or loss of this supplier could significantly delay the delivery of products, which in turn would materially affect the Company’s ability to generate revenue. Recently Adopted Accounting Pronouncements In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 842): Disclosures by Business Entities about Government Assistance In October 2020, the FASB issued ASC Update (“ASU”) No. 2020-10, Codification Improvements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Recent Accounting Pronouncements The following are new FASB ASUs that had not been adopted by the Company as of December 31, 2021: In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, and adoption must be as of the beginning of the Company’s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses

Inventory

Inventory	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Inventory	Note 3. Inventory Inventory, net of allowance, consisted of the following as of the date indicated: December 31, 2021 2020 Raw materials $ 1,964,407 $ 1,079,528 Work in process 312,803 147,455 Finished goods 447,145 291,195 Total gross inventory 2,724,355 1,518,178 Less inventory allowance (25,306 ) (26,052 ) $ 2,699,049 $ 1,492,126 Inventory of $2.0 million and $0.7 million was included in inventory – current and other non-current assets, respectively, in the consolidated balance sheets as of December 31, 2021. There was no inventory classified as long-term as of December 31, 2020. For the years ended December 31, 2021 and 2020, the Company recorded adjustments to the provision for excess inventory of $174,589 and $53,298, respectively. Adjustments in these periods to the allowance for estimated shrinkage, obsolescence and excess inventory and to the inventory reserve have been included in cost of product and product-related services revenue in the consolidated statements of operations.

Fair Value

Fair Value	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Fair Value	Note 4. Fair Value Financial assets and liabilities measured at fair value are classified in their entirety in the fair value hierarchy, based on the lowest level input significant to the fair value measurement. The following table classifies the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2021 and 2020, respectively, in the fair value hierarchy: December 31, 2021 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 9,083,302 $ — $ — $ 9,083,302 Investments available-for-sale at fair value Corporate debt securities — 12,343,456 — 12,343,456 Total $ 9,083,302 $ 12,343,456 $ — $ 21,426,758 December 31, 2020 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 17,497,282 $ — $ — $ 17,497,282 Corporate debt securities 4,499,270 4,499,270 Investments available-for-sale at fair value Corporate debt securities — 6,298,075 — 6,298,075 Total $ 17,497,282 $ 10,797,345 $ — $ 28,294,627 There were no other financial instruments subject to fair value measurement on a recurring basis. Transfers to and from Levels 1, 2 and 3 are recognized at the end of the reporting period. There were no transfers between levels for the years ended December 31, 2021 and 2020. Level 1 instruments include investments in money market funds . Fair values of these assets are based on prices provided by independent market participants that are based on observable inputs using market-based valuation techniques. These valuation models and analytical tools use market pricing or similar instruments that are both objective and publicly available, including matrix pricing or reported trades, benchmark yields, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids and/or offers. The Company did not adjust any of the valuations received from these third parties with respect to any of its Level 1 or 2 securities for either of the years ended December 31, 2021 or 2020 and did not have any Level 3 financial assets or liabilities during either of these periods.

Available-for-Sale Securities

Available-for-Sale Securities	12 Months Ended
	Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]
Available-for-Sale Securities	Note 5. Available-for-Sale Securities The Company’s portfolio of available-for-sale securities consists of high credit quality corporate debt securities as of December 31, 2021. The following is a summary of the Company’s available-for-sale securities as of December 31, 2021 and 2020: December 31, 2021 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities 12,343,456 — — 12,343,456 Total available-for-sale securities $ 12,343,456 $ — $ — $ 12,343,456 December 31, 2020 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities 6,298,075 — — 6,298,075 Total available-for-sale securities $ 6,298,075 $ — $ — $ 6,298,075 There were no gross unrealized losses relating to the Company’s available-for-sale securities investments as of December 31, 2021. The net adjustment to unrealized holding gains on short-term investments, net of tax in other comprehensive income were immaterial for each of the years ended December 31, 2021 and 2020. Contractual maturities of debt investment securities as of December 31, 2021 are shown below. Expected maturities will differ from contractual maturities because the issuers of the securities may have the right to prepay obligations without prepayment penalties. Under 1 Year 1 to 2 Years Total Corporate debt securities 12,343,456 — 12,343,456 Total available-for-sale securities $ 12,343,456 $ — $ 12,343,456 The Company conducts a regular assessment of its debt securities with unrealized losses to determine whether securities have OTTI considering, among other factors, the nature of the securities, credit rating or financial condition of the issuer, the extent and duration of the unrealized loss, expected cash flows of underlying collateral, market conditions and whether the Company intends to sell or it is more likely than not that the Company will be required to sell the debt securities. As the Company did not have any unrealized losses as of December 31, 2021, there was no OTTI of its available-for-sale securities as of that date.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2021
Property Plant And Equipment [Abstract]
Property and Equipment	Note 6. Property and Equipment Property and equipment, net consisted of the following as of the dates indicated: December 31, 2021 2020 Furniture & fixtures $ 872,877 $ 1,082,717 Leasehold improvements 1,931,762 1,943,534 Equipment used in manufacturing 2,432,242 2,166,743 Equipment used in research & development 2,343,930 2,506,644 Equipment used in the field 216,218 208,005 Software 480,740 420,301 Property and equipment 8,277,769 8,327,944 Less: accumulated depreciation and amortization (7,158,883 ) (7,100,542 ) $ 1,118,886 $ 1,227,402 Depreciation and leasehold improvement amortization expense was $0.7 million and $1.3 million for the years ended December 31, 2021 and 2020, respectively.

Accrued Liabilities

Accrued Liabilities	12 Months Ended
	Dec. 31, 2021
Accrued Liabilities Current [Abstract]
Accrued Liabilities	Note 7. Accrued Liabilities Accrued liabilities consisted of the following as of the dates indicated: December 31, 2021 2020 Accrued employee bonuses $ 1,254,355 $ 436,799 Payroll and employee benefit accruals 389,385 694,058 Accrued product warranty 97,512 92,696 Other accrued liabilities 281,317 236,325 $ 2,022,569 $ 1,459,878

Debt Obligations

Debt Obligations	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Debt Obligations	Note 8. Debt Obligations. Current portion of long-term debt consisted of the following as of the dates indicated: December 31, 2021 2020 SVB Term Loan $ 5,000,000 $ 2,000,000 PPP Loan — 857,040 2021 Insurance Note 167,586 — 2020 Insurance Note — 165,099 $ 5,167,586 $ 3,022,139 Long-term debt, net of current portion, discount and debt issuance costs, consisted of the following as of the dates indicated: December 31, 2021 2020 SVB Term Loan, net of discount and debt issuance costs $ 5,178,629 $ 7,708,348 PPP Loan — 859,960 $ 5,178,629 $ 8,568,308 SVB Term Loan On June 24, 2020 (the “Closing Date”), the Company entered into the Loan Agreement with SVB. The proceeds from the SVB Term Loan in the amount of $10.0 million were fully funded on June 25, 2020. Together with cash on hand, the proceeds were used to repay in full all outstanding amounts and fees due under the MidCap Credit Facility in an aggregate amount equal to $7.5 million, including collateral agent legal fees and prepayment fees, in addition to the Company’s subordinated convertible promissory note to QNAH (the “QNAH Convertible Note”) and related accrued interest in the aggregate amount of $3.2 million. As a result of the repayment, the Company recorded a loss on extinguishment of the MidCap Credit Facility and the QNAH Convertible Note of $0.5 million in other income (expense) in the accompanying consolidated statements of operations for the year ended December 31, 2020. All obligations under the MidCap Credit Facility and the QNAH Convertible Note were fulfilled as a result of this extinguishment. The SVB Term Loan bears interest at a floating rate equal to the greater of 2.50% above the Prime Rate (as defined in the Loan Agreement) and 5.75%. Interest on the SVB Term Loan is due and payable monthly in arrears. The SVB Term Loan originally required interest-only payments through June 30, 2021. As a result of the Company’s achievement of an equity milestone defined in the Loan Agreement during the quarter ended June 30, 2021, the interest-only period was extended for six months through December 31, 2021. Following the extended interest-only period, the Company is obligated to make equal monthly payments of principal and interest through the maturity date of December 1, 2023. Prepayments of the SVB Term Loan, in whole or in part, are subject to early termination fees in an amount equal to 2.0% of principal prepaid if prepayment occurs after the first anniversary of the Closing Date but on or prior to the second anniversary of the Closing Date, and 1.0% of principal prepaid if prepayment occurs after the second anniversary of the Closing Date and prior to the maturity date. Upon termination of the Loan Agreement, the Company is required to pay a final fee equal to 8.00% of the principal amount of the SVB Term Loan. The Company’s obligations under the Loan Agreement are secured by a security interest in substantially all of its assets, excluding intellectual property (which is subject to a negative pledge), and the Company’s future subsidiaries, if any, may be required to become co-borrowers or guarantors under the Loan Agreement. In addition, the Company must comply with a financial covenant in the SVB Term Loan requiring the Company to maintain unrestricted cash, including short term available-for-sale securities, of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months. In connection with the Loan Agreement, the Company granted to SVB a warrant to purchase up to 42,894 shares of the Company’s common stock at a purchase price of $11.6565 per share. The warrant will expire on June 24, 2030 and may be exercised for cash or at the election of the holder on a cashless, net exercise basis. The fair value of the warrant on the date of issuance was approximately $0.4 million, determined using the Black-Scholes option-pricing model, and was recorded as a discount to the SVB Term Loan, with a corresponding credit to additional paid in capital since the warrant met the requirements to be classified as equity The Company included $0.6 million and $1.1 million of debt discount associated with the SVB Term Loan, resulting from fees and debt issuance costs, inclusive of the fair value of warrants issued, in long-term debt, net of current portion, discount and debt issuance costs in the accompanying as of December 31, 2021 and 2020, respectively. Amortization of the debt discount associated with the SVB Term Loan was $0.5 million and $0.2 million for the years ended December 31, 2021 and 2020, respectively, and was included in interest expense in the . The effective interest rate for the year ended December 31, 2021 was 10.47%. The remaining principal repayments due under the SVB Term Loan as of December 31, 2021 are as follows for each fiscal year: 2022 $ 5,000,000 2023 5,000,000 Total SVB Term Loan payments 10,000,000 Less discount and deferred financing costs (621,371 ) Plus final fee premium 800,000 Total SVB Term Loan, net $ 10,178,629 Paycheck Protection Program Loan On April 21, 2020, the Company received proceeds from a PPP Loan in the amount of $1.7 million from SVB, as lender. The PPP Loan was evidenced by a promissory note which bore interest at an annual rate of 1%, and contained customary events of default relating to, among other things, payment defaults and breaches of representations, warranties or terms of the PPP Loan documents. Under the CARES Act and PPP Flexibility Act, loan forgiveness was available for the sum of documented payroll costs (including benefits), rent and utility obligations, and interest on certain of the Company’s other debt obligations incurred during the 24-week period beginning on the date of loan approval, as defined by the applicable guidelines and the SBA. The Company applied for full PPP Loan forgiveness in October 2020. On May 26, 2021, the Company received notification from SVB that the PPP Loan and related accrued interest was forgiven in full by the SBA, and the PPP Loan note had been cancelled. Accordingly, the Company recorded a gain on forgiveness of the PPP Loan of $1.7 million for the year ended December 31, 2021, included in other income (expense) in the accompanying consolidated statements of operations. The PPP Loan is subject to SBA review at any time before or after the SBA remits payment to the lender. The Company has not accrued any liability associated with risk of an adverse SBA review. Insurance Note On April 27, 2020, the Company entered into a commercial financing agreement to extend the payment period related to its director and officer insurance policy (the “2020 Insurance Note”). The 2020 Insurance Note required a down payment to be made upon signing the agreement equal to approximately $0.2 million. The unpaid premium balance of approximately $0.7 million was financed at an annual rate of 3.61% and was repaid in nine equal monthly payments of principal and interest through February 2021 On May 5, 2021, the Company entered into a new commercial financing agreement to extend the payment period related to its director and officer insurance policy (the “2021 Insurance Note”). The 2021 Insurance Note required a down payment to be made upon signing the agreement equal to approximately $0.4 million. The remaining unpaid premium balance of approximately $0.7 million has been financed at an annual rate of 3.57% and is to be repaid in nine equal monthly payments of principal and interest beginning in June 2021

Revenue from Contracts with Cus

Revenue from Contracts with Customers	12 Months Ended
	Dec. 31, 2021
Revenue From Contract With Customer [Abstract]
Revenue from Contracts with Customers	Note 9. Revenue from Contracts with Customers Revenue from contracts with customers is recognized when, or as, the Company satisfies its performance obligations by delivering the promised goods or service deliverables to the customers. A good or service deliverable is transferred to a customer when, or as, the customer obtains control of that good or service deliverable. A performance obligation may be satisfied over time or at a point in time. Revenue from a performance obligation satisfied over time is recognized by measuring the Company’s progress in satisfying the performance obligation in a manner that depicts the transfer of the goods or services to the customer. Revenue from a performance obligation satisfied at a point in time is recognized at the point in time that the Company determines the customer obtains control over the promised good or service deliverable. The amount of revenue recognized reflects the consideration the Company expects to be entitled to in exchange for those promised goods or services ( i.e. Product and Product-related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the years ended December 31, 2021 and 2020 as follows: Years Ended December 31, 2021 2020 Product revenue: Instrument $ 1,385,665 $ 869,035 Consumables 3,786,923 3,030,612 Total product revenue 5,172,588 3,899,647 Product-related services revenue: Custom RUO assay design 48,350 1,393,316 RUO sample processing 3,685,890 2,597,891 Total product-related services revenue 3,734,240 3,991,207 Total product and product-related services revenue $ 8,906,828 $ 7,890,854 As the Company’s agreements for product and product-related services revenue have an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations. Sale of instruments and consumables The delivery of each instrument and related installation and calibration are considered to be a single performance obligation, as the HTG EdgeSeq instrument must be professionally installed and calibrated prior to use. Instrument product revenue is generally recognized upon installation and calibration of the instrument by field service engineers, which represents the point at which the customer has the ability to use the instrument and has accepted the asset. Installation generally occurs within one month of instrument shipment. The delivery of each consumable is a separate performance obligation. Consumables revenue is recognized upon transfer of control, which represents the point when the customer has legal title and the significant risks of ownership of the asset. The Company’s standard terms and conditions provide that no right of return exists for instruments and consumables, unless replacement is necessary due to delivery of defective or damaged product. Customer payment terms vary but are typically between 30 and 90 days of revenue being earned from shipment or delivery, as applicable. Shipping and handling fees charged to the Company’s customers for instruments and consumables shipped are included in the consolidated statements of operations as part of product and product-related services revenue. Shipping and handling costs for sold products shipped to the Company’s customers are included in the consolidated statements of operations as part of cost of product and product-related services For sales of consumables in the United States, standard delivery terms are FOB shipping point, unless otherwise specified in the customer contract, reflecting transfer of control to the customer upon shipment. Standard delivery terms for sales to customers outside of the United States are FOB delivery point, unless otherwise specified in the customer contract. The Company has elected the practical expedient to account for shipping and handling as activities to fulfill the promise to transfer the consumables. The Company provides instruments to certain customers under reagent rental agreements. Under these agreements, the Company installs instruments in the customer’s facility without a fee and the customer agrees to purchase consumable products at a stated price over the term of the agreement; in some instances, the agreements do not contain a minimum purchase requirement. Terms range from several months to multiple years and may automatically renew in several month or multiple year increments unless either party notifies the other in advance that the agreement will not renew. The Company measures progress toward complete satisfaction of this performance obligation to provide the instrument and deliver the consumables using an output method based on the number of consumables delivered in relation to the total consumables to be provided under the reagent rental agreement. This is considered to be representative of the delivery of outputs under the arrangement and the best measure of progress because the customer benefits from the instrument only in conjunction with the consumables. The Company expects to recover the cost of the instrument under the agreement through the fees charged for consumables, to the extent sold, over the term of the agreement. In reagent rental agreements, the Company retains title to the instrument and title is transferred to the customer at no additional charge at the conclusion of the initial arrangement. The cost of the instrument is amortized on a straight-line basis over the term of the arrangement, unless there is no minimum consumable product purchase, in which case the instrument would be expensed as cost of product and product-related services RUO Sample Processing The Company also provides sample preparation and processing services and molecular profiling of retrospective cohorts for its customers through its VERI/O laboratory, whereby the customer provides samples to be processed using HTG EdgeSeq technology specified in the order. Customers are charged a per sample fee for sample processing services which is recognized as revenue upon delivery of a data file to the customer showing the results of testing and completing delivery of the agreed upon service. This is when the customer can use and benefit from the results of testing and the Company has the present right to payment. Custom RUO Assay Design and Related Agreements The Company enters into custom RUO assay design agreements that may generate up-front fees and subsequent payments that might be earned upon completion of design process phases. The Company measures progress toward complete satisfaction of its performance obligation to perform custom RUO assay design using an output method based on the costs incurred to date compared with total expected costs, as this is representative of the delivery of outputs under the arrangements and the best measure of progress. However, because in most instances the assay development fees are contingent upon completion of each phase of the design project and the decision of the customer to proceed to the next phase, the amount to be included in the transaction price and recognized as revenue is limited to that which the customer is contractually obligated to pay upon completion of that phase, which is when it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur. The Company did not recognize any custom RUO assay design revenue from performance obligations that were satisfied in previous periods during the years ended December 31, 2021 and 2020. Collaborative Development Services Revenue The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606 and ASC 808 to determine the appropriate recognition of revenue under its collaborative research, development and commercialization agreements. For the year ended December 31, 2020, collaborative development services revenue was generated through statements of work entered into under a Master Assay Development, Commercialization and Manufacturing Agreement (the “Governing Agreement”) with QIAGEN Manchester Limited (“QML”) discussed below. Years Ended December 31, 2021 2020 Collaborative development services $ — $ 658,010 Master Assay Development, Commercialization and Manufacturing Agreement The Governing Agreement created the framework for QML and the Company to combine their technological and commercial strengths to offer biopharmaceutical companies a complete NGS-based solution for the development, manufacture and commercialization of companion diagnostic assays. Under the Governing Agreement, the parties jointly sought companion diagnostic programs with biopharmaceutical companies, with QML entering into sponsor project agreements with interested biopharmaceutical companies for specified projects, and QML and the Company entering into statements of work which set forth the rights and obligations of QML and the Company with respect to each project. In November 2019, the Company elected to terminate the Governing Agreement with QML. The Company’s termination of the Governing Agreement did not terminate active statements of work under the Governing Agreement. Remaining agreed upon procedures associated with these statements of work were completed in the prior year and no additional collaborative development services programs have been entered into as of December 31, 2021. Because each SOW has an expected duration of one year or less, the Company has elected the practical expedient in ASC 606-10-50-14(a) to not disclose information about its remaining performance obligations for each SOW. Contract Liabilities The Company may receive up-front payments from customers for custom RUO assay design and sample processing services. In addition, payments for instrument extended warranty contracts are required to be made in advance. The Company recognizes such up-front payments as contract liabilities. The contract liabilities are subsequently reduced at the point in time that the data files are delivered for sample processing services or as the Company satisfies its performance obligations over time for RUO assay design and extended warranty services. Contract liabilities of $0.1 million were included in contract liabilities – current and an additional immaterial amount of contract liabilities were included in other non-current liabilities in the consolidated balance sheets as of December 31, 2021, reflecting the period in which the Company expects to realize the deferred revenue. Changes in the Company’s contract liabilities were as follows as of the dates indicated: Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2021 $ 103,580 $ - $ 93,884 $ 197,464 Deferral of revenue 286,349 - 587,091 873,440 Recognition of deferred revenue (261,400 ) - (650,354 ) (911,754 ) Balance at December 31, 2021 $ 128,529 $ — $ 30,621 $ 159,150 Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2020 $ 95,148 $ 66,216 $ 438,090 $ 599,454 Deferral of revenue 500,045 566,733 124,404 1,191,182 Recognition of deferred revenue (491,613 ) (632,949 ) (186,888 ) (1,311,450 ) Transfer to refund liability — — (281,722 ) (281,722 ) Balance at December 31, 2020 $ 103,580 $ — $ 93,884 $ 197,464

Other Agreements

Other Agreements	12 Months Ended
	Dec. 31, 2021
Other Agreements [Abstract]
Other Agreements	Note 10. Other Agreements NuvoGen Obligation The Company entered into an asset purchase agreement in 2001, as amended, with NuvoGen Research, LLC (“NuvoGen”) to acquire certain intellectual property from NuvoGen. The Company accounted for the transaction as an asset acquisition. However, as the intellectual property was determined to not have an alternative future use, the upfront consideration was expensed. In exchange for the intellectual property, the Company agreed to pay total aggregate cash compensation to NuvoGen under the agreement of $15.0 million. Certain terms of the agreement were amended in November 2003, September 2004, November 2012 and February 2014. Pursuant to the latest amendment to the agreement, the Company is obligated to pay the greater of $0.4 million or 6% of annual revenue until the obligation is paid in full. The Company paid yearly fixed fees, in quarterly installments, to NuvoGen of $0.4 million as well as revenue-based payments of $0.1 million and $0.2 million during the years ended December 31, 2021 and 2020, respectively, for the amount by which 6% of revenue exceeded the applicable fixed fee. Beginning on January 1, 2019 and continuing until the remaining obligation has been paid in full, interest on the remaining unpaid obligation is being accrued and will compound annually at a rate of 2.5% per year. Accrued interest related to this obligation is payable on the date that the remaining obligation is paid in full. Minimum payments to be made in 2022 include $72,624 of revenue-based payments payable as of December 31, 2021 and an estimate of additional revenue-based payments to be made throughout the remainder of 2022 relating to revenue generated in the first, second and third quarters of 2022 using actual revenue generated in the same quarters in 2021. Minimum payments for the remaining years include only the minimum payments for each year. Actual payments could be significantly more than provided in the table, to the extent that 6% of the Company’s annual revenue in those years exceeds $0.4 million: 2022 $ 548,301 2023 400,000 2024 400,000 2025 400,000 2026 400,000 2027 and beyond 2,233,792 Total NuvoGen obligation payments 4,382,093 Plus interest accretion 67,088 Total NuvoGen obligation, net $ 4,449,181 The Company has recorded the obligation at the estimated present value of the future payments using a discount rate of 2.5%, which represents the Company’s estimate of its effective borrowing rate for similar obligations. The unamortized interest accretion was $(67,088) and $(79,376) as of December 31, 2021 and 2020, respectively. Discount accreted during the years ended December 31, 2021 and 2020 was $(12,288), and $(12,935), respectively, and was included in interest expense in the consolidated statements of operations.

Leases

Leases	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Leases	Note 11. Leases Operating Leases T he Company leases office space under agreements classified as operating leases. The Company’s active leases as of December 31, 2021 relate to the Company’s office and manufacturing space in Tucson, Arizona, and expire in 2025. The Company’s leases do not include any contingent rental payments, impose any financial restrictions, or contain any residual value guarantees. The Company amended its Tucson facility leases in December 2020 to extend the terms of the leases for one year, through January 31, 2022 and again in September 2021 to extend the terms of the leases for three years, through January 31, 2025. The lease extensions were treated as lease modifications for accounting purposes, and allow for an additional extension of two years on the same terms and conditions of the existing amended lease agreement, except that the lease rates would be adjusted to reflect lease rates applicable to like-kind buildings within the market at the time that the Company elects to exercise the extension options, but in no event less than the last applicable rental rate. The Company has not accounted for these renewal options in the calculation of the lease liabilities and right-of-use assets as the Company is not reasonably certain to exercise the options. In the first quarter of 2021, the Company closed its development laboratory in San Carlos, California and, as a result, $0.2 million of operating right-of-use assets related to the abandonment of the laboratory were written off to research and development expense for the year ended December 31, 2021. Variable expenses generally represent the Company’s share of the landlord’s operating expenses and are recorded when incurred. Incremental borrowing rates used to discount future lease payments in calculating lease liabilities were estimated by reference to the rates for similar length secured lines of credit to the Company’s lease agreements provided by the Company’s lenders at the time that the lease liabilities were recorded, as these rates represented the cost of borrowing for secured loans of similar duration. The Company does not have any operating lease arrangements where it acts as a lessor. The components of lease cost for operating leases were as follows: Years Ended December 31, 2021 2020 Operating leases Operating lease cost $ 503,130 $ 752,413 Variable lease cost 88,708 125,792 Total rent expense $ 591,838 $ 878,205 The table below summarizes other information related to the Company’s operating leases: Years Ended December 31, 2021 2020 Cash paid for amounts included in measurement of operating lease liabilities $ 514,453 $ 883,252 Establishment of operating lease liabilities arising from obtaining right-of-use assets $ 1,302,457 $ 447,987 Weighted-average remaining lease term – operating leases 3.1 1.7 Weighted-average discount rate – operating leases 5.8 % 8.0 % As of December 31, 2021, remaining maturities of the Company’s operating leases are as follows: 2022 $ 481,548 2023 484,719 2024 484,631 2025 40,382 Total 1,491,280 Less present value discount (127,954 ) Total operating lease liabilities 1,363,326 Less operating lease liabilities – current (413,865 ) Operating lease liabilities - non-current $ 949,461 Financing Leases The Company has a number of computer and copier equipment leases that are classified as financing leases. Incremental borrowing rates used to discount future lease payments in calculating lease liabilities were estimated by reference to information received by the Company from bankers regarding estimated current borrowing rates for collateralized loans with similar amount and duration as the leases. Years Ended December 31, 2021 2020 Financing leases Amortization of right-of-use assets $ 23,118 $ 42,826 Interest on lease liability 5,793 8,938 Total financing lease cost $ 28,911 $ 51,764 The table below summarizes other information related to the Company’s financing leases: Years Ended December 31, 2021 2020 Weighted-average remaining lease term – financing leases 2.8 3.4 Weighted-average discount rate – financing leases 9.77 % 9.77 % As of December 31, 2021, remaining maturities of the Company’s financing leases are as follows: 2022 $ 20,716 2023 18,396 2024 16,080 Total 55,192 Less present value discount (7,081 ) Financing lease liabilities, net $ 48,111 F inancing lease liabilities net of discount of $48,111, of which $16,807 and $31,304 were included in other current liabilities and other non-current liabilities, respectively, and financing right-of-use assets of $43,651, were included in property and equipment, net, in the consolidated balance sheet as of December 31, 2021.

Net Loss per Share

Net Loss per Share	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Net Loss per Share	Note 12. Net Loss Per Share Basic loss per common share is computed by dividing the net loss allocable to common stockholders by the weighted-average number of shares of common stock or common stock equivalents outstanding. Diluted loss per common share is computed similar to basic loss per common share except that it reflects the potential dilution that could occur if dilutive securities or other obligations to issue common stock were exercised or converted into common stock. The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Years Ended December 31, 2021 2020 Numerator: Net loss $ (17,145,170 ) $ (20,870,218 ) Denominator: Weighted-average shares outstanding-basic and diluted * 6,936,131 4,627,918 Net loss per share, basic and diluted $ (2.47 ) $ (4.51 ) *Reflects the retrospective adjustment related to the reverse stock split completed on November 20, 2020. The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Years Ended December 31, 2021 2020 Options to purchase common stock 559,336 487,227 Series A Preferred 158,545 158,545 Common stock warrants 58,688 58,688 Unvested restricted stock units 31,177 12,214

Warrants

Warrants	12 Months Ended
	Dec. 31, 2021
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Warrants	Note 13. Warrants In connection with certain of its redeemable convertible preferred stock issuances, debt agreements, convertible debt and other financing arrangements, the Company has issued warrants for shares of its common stock and various issues of its redeemable convertible preferred stock which have since been converted to common stock warrants. In connection with the Securities Purchase Agreement (see Note 14), the Company issued and sold pre-funded warrants exercisable for an aggregate of 360,779 shares of common stock. The total exercise price of the pre-funded warrants is $9.75 per share, $9.60 of which was pre-funded and paid to the Company upon issuance of the pre-funded warrants. The remaining exercise price of the pre-funded warrants is $0.15 per share. In March 2020, 211,784 of the pre-funded warrants were exercised for proceeds of $31,768. In June 2021, the remaining 148,995 pre-funded warrants were exercised on a cashless, net exercise basis, resulting in the issuance of 144,881 shares of common stock. In connection with the SVB Term Loan (see Note 8), the Company granted to SVB a warrant to purchase up to 42,894 shares of the Company’s common stock at a purchase price of $11.6565 per share. The warrant will expire on June 24, 2030 and may be exercised for cash or at the election of the holder on a cashless, net exercise basis. The following table shows the common stock warrants outstanding as of December 31, 2021: Warrant Issuance Date Shares of Common Underlying Warrants Exercise Price/Share Expiration Date August 2014 1,914 $ 352.65 2024 December 2014 9,651 210.00 2022 March 2016 3,021 41.40 2026 March 2018 1,208 115.95 2028 June 2020 42,894 11.6565 2030

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2021
Equity [Abstract]
Stockholders' Equity	Note 14. Stockholders’ Equity Reverse Stock Split On November 20, 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen (15) shares of issued and outstanding common stock were exchanged for one share of its common stock. No fractional shares were issued in the reverse stock split. Instead, fractional shares that would have otherwise resulted from the stock split were purchased by us at the applicable percentage of $4.27 per share. All share and per share amounts included within these financial statements have been retrospectively adjusted to reflect the reverse stock split. Equity Offerings Securities Purchase Agreement In September 2019, concurrently with the closing of an underwritten public offering, the Company entered into a Securities Purchase Agreement (the “Securities Purchase Agreement”) with certain institutional accredited investors (the “Purchasers”), pursuant to which the Company sold to the Purchasers, in a private placement transaction, warrants to purchase up to an aggregate of 360,779 shares of its common stock (“Warrant Shares”), at a price of $9.60 per warrant (which $9.60 price relates to the pre-funded portion of the total $9.75 exercise price per share). Each pre-funded warrant has a remaining exercise price of $0.15 per share and became immediately exercisable upon issuance, subject to certain beneficial ownership limitations. For further discussion of pre-funded warrant activity see Note 13. ATM Offering In November 2019, the Company entered into a Controlled Equity Offering Sales Agreement (the “Cantor Sales Agreement”) with Cantor as sales agent, pursuant to which the Company was able to offer and sell, from time to time, through Cantor, shares of its common stock, par value $0.001 per share, by any method deemed to be an “at the market offering” as defined by rule 415(a)(4) under the Securities Act (the “ATM Offering”). The Company paid Cantor a commission of 3.0% of the aggregate gross proceeds from each sale of shares for all sales made under this agreement. The shares were offered and sold pursuant to the Company’s prior shelf registration statement on Form S-3 (File No. 333-229045). During the year ended December 31, 2021, the Company sold 2,050,879 shares of common stock under the ATM Offering at then-market prices for total gross proceeds of approximately $11.0 million. After paying sales commissions owed in connection with the ATM Offering of approximately $0.3 million, the Company’s aggregate net proceeds for the year ended December 31, 2021 were approximately $10.7 million. During the year ended December 31, 2020, the Company sold 955,240 shares of common stock under the ATM Offering at then‑market prices for total gross proceeds of $7.9 million. After deferred offering costs of $0.1 million and paying sales commissions owned in connection with the ATM Offering of $0.2 million, the Company’s aggregate net proceeds for the year ended December 31, 2020 were $7.5 million. Exchange and Private Placement On February 25, 2020, the Company entered into an Exchange and Purchase Agreement (the “Exchange Agreement”) with certain accredited investors (the “Investors”) pursuant to which the Company agreed to (i) issue to the Investors an aggregate of 41,100 shares of its newly designated Series A Convertible Preferred Stock, par value $0.001 per share (“Series A Preferred”), in exchange for the Investors surrendering to the Company for cancellation an aggregate of 274,000 shares of its common stock (the “Exchange”) and (ii) sell and issue to the Investors an aggregate of 10,170 shares of Series A Preferred for an aggregate purchase price of $0.6 million, or $59.00 per share (the “Private Placement”), both of which were completed prior to the end of February 2020. In February 2020, in connection with the Exchange Agreement and the planned issuance of shares of Series A Preferred pursuant to the Exchange and Private Placement, the Company filed a Certificate of Designation of Preferences, Rights and Limitations of Series A Convertible Preferred Stock (the “Series A Certificate of Designation”). The Series A Certificate of Designation establishes and designates the Series A Preferred and the rights, preferences and privileges thereof. Each share of Series A Preferred is convertible into 6.67 shares of the Company’s common stock, subject to proportional adjustment and beneficial ownership limitations. In June 2020, certain of the Investors elected to convert 27,500 shares of Series A Preferred to common stock in the aggregate, resulting in the issuance of 183,333 shares of the Company’s common stock. The remaining 23,770 Series A Preferred shares remain outstanding as of December 31, 2021. In the event of the Company’s liquidation, dissolution or winding up, holders of Series A Preferred will participate pari passu with any distribution of proceeds to holders of the Company’s common stock. Holders of Series A Preferred are entitled to receive dividends on shares of Series A Preferred equal (on an as converted to common stock basis) to and in the same form as dividends actually paid on the Company’s common stock. Shares of Series A Preferred generally have no voting rights, except as required by law. LP Purchase Agreement On March 24, 2020, the Company entered into a purchase agreement ("LP Purchase Agreement") with Lincoln Park Capital Fund, LLC ("Lincoln Park"), pursuant to which, upon the terms and subject to the conditions and limitations set forth therein, the Company has the right to sell to Lincoln Park up to $20.0 million of shares of its common stock (“Purchase Shares”) from time to time over the 36-month term of the LP Purchase Agreement. The Company may sell up to 20,000 shares of its common stock to Lincoln Park in a regular purchase on any single business day that the closing price of its stock is not below $1.50. The minimum purchase amount per day must be equal to or greater than $150,000 to the extent the Company chooses to sell shares to Lincoln Park. This amount may be increased to up to 23,333 shares if the closing price of the Company’s common stock is not below $7.50 and to up to 26,666 shares if the closing price of the Company’s common stock is not below $11.25. In each case, the maximum amount of any single business day’s Purchase Shares may be increased up to 166,666 shares. The Company may direct Lincoln Park to purchase shares as often as every business day subject to the limitations outlined above. For each sale of common stock during the period of the agreement, the purchase price of the Purchase Shares will be established by a formula based on the recent closing prices of the Company’s common stock leading up to the date of sale. In addition to the regular purchases, the Company may also direct Lincoln Park to purchase other amounts as accelerated purchases or as additional accelerated purchases if the closing sales price of the Company’s common stock exceeds certain threshold prices as set forth in the LP Purchase Agreement. Under applicable rules of The Nasdaq Capital Market, in no event may the Company issue or sell to Lincoln Park under the LP Purchase Agreement shares of its common stock in excess of 19.99% of the shares of the Company’s common stock outstanding immediately prior to execution of the LP Purchase Agreement (the “Exchange Cap”), unless (i) the Company obtains stockholder approval to issue shares of its common stock in excess of the Exchange Cap or (ii) the average price of all applicable sales of its common stock to Lincoln Park under the LP Purchase Agreement equals or exceeds $5.2155, such that issuances and sales of the common stock to Lincoln Park under the purchase agreement would be exempt from the issuance limitation under applicable Nasdaq rules. The Company determined that the right to sell additional shares represents a freestanding put option under derivative accounting guidance, but has a fair value of zero, and therefore no additional accounting was required. Lincoln Park has no right to require the Company to sell any shares of its common stock to Lincoln Park, but Lincoln Park is obligated to make purchases as directed by the Company, subject to the limitations outlined above. In all instances, the Company may not sell shares of its common stock to Lincoln Park under the LP Purchase Agreement if doing so would result in Lincoln Park beneficially owning more than 9.99% of the Company’s common stock. The Company issued Lincoln Park an aggregate of 41,026 shares of its common stock as consideration for their purchase commitment pursuant to the LP Purchase Agreement. The Company did not receive cash proceeds from the issuance of such shares. The value of this commitment consideration, as well as related transaction costs of approximately $0.1 million was included in s elling, general and administrative expense in the accompanying consolidated statements of operations during the year ended December 31, 2020 During the year ended December 31, 2021, the Company sold 197,632 Pursuant to the March 2022 Purchase Agreement (see Note 17), the Company may not sell any shares of its common stock under the LP Purchase Agreement for the remainder of the 36-month term of the LP Purchase Agreement. Common Stock Pursuant to its amended and restated certificate of incorporation, the Company is authorized to issue 26,666,667 shares of common stock at a par value of $0.001 per share. Each share of common stock is entitled to one vote. The shares of common stock have no preemptive or conversion rights, no redemption or sinking fund provisions, no liability for further call or assessment, and are not entitled to cumulative voting rights. Preferred Stock Pursuant to its amended and restated certificate of incorporation, the Company has been authorized to issue 10,000,000 shares of preferred stock, each having a par value of $0.001. The preferred stock may be issued from time to time in one or more series with the authorization of the Company’s Board of Directors. The Board of Directors can determine voting power for each series issued, as well as designation, preferences, and relative, participating, optional or other rights and such qualifications, limitations or restrictions thereof. Stock-based Compensation The Company incurs stock-based compensation expense relating to the grants of RSUs and stock options to employees, non-employee directors and consultants under its equity incentive plans and through stock purchase rights granted under the ESPP. Equity Incentive Plans The Company initially established the 2001 Stock Option Plan (the “2001 Plan”), which included incentive and nonqualified stock options and restricted stock to be granted to directors, officers, employees, consultants and others. The 2001 Plan terminated, and no further awards were granted under the 2001 Plan upon the effective date of the Company’s 2011 Equity Incentive Plan (the “2011 Plan”). In May 2015, the 2011 Plan terminated, and no further awards were granted under the 2011 plan upon the effective date of the Company’s 2014 Equity Incentive Plan (the “2014 Plan”). In August 2020, the Company’s stockholders, upon the recommendation of the Company’s Board of Directors, approved the 2020 Equity Incentive Plan (the “2020 Plan”) as a successor to and continuation of the 2014 Plan. Upon approval of the 2020 Plan, 744,685 shares, including 68,552 remaining shares reserved for issuance under the 2014 Plan (excluding shares available for the granting of Inducement Awards under the 2014 Plan’s inducement share pool), were reserved for issuance under the 2020 Plan. No new awards may be granted under the 2014 Plan. There were 558,865 shares of the Company’s common stock available for issuance under the 2020 Plan as of December 31, 2021 in addition to shares that may become available from time to time as shares of our common stock subject to outstanding awards granted under the 2014 Plan (excluding Inducement Awards), the 2011 Plan or the 2001 Plan that, following the effective date of the 2020 Plan (i) are not issued because such award or any portion thereof expires or otherwise terminates without all of the shares covered by such award having been issued; (ii) are not issued because such award or any portion thereof is settled in cash; or (iii) are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares. The 2020 Plan does not contain an evergreen provision. In July 2021, the Company’s Board of Directors adopted the Company’s 2021 Inducement Plan (the “2021 Inducement Plan”), pursuant to which 300,000 shares were initially authorized and reserved for issuance exclusively for the grant of awards to individuals who were not previously employees or non-employee directors of the Company, as inducement material to the individuals’ entering into employment with the Company (“Inducement Awards”). There were 160,000 shares of the Company’s stock available for issuance under the 2021 Inducement Plan as of December 31, 2021, in addition to shares that may become available from time to time as shares of the Company’s common stock subject to outstanding awards granted under the 2021 Inducement Plan are forfeited back to or repurchased by the Company because of the failure to meet a contingency or condition required for the vesting of such shares. The Company’s Board of Directors determines the grant date for all awards granted under the 2020 Plan. The exercise price of stock options granted is generally equal to the closing price of the Company’s common stock on the date of grant or on the employee’s hire date for new hire grants. All stock options granted have a ten-year Amounts recognized in the consolidated statements of operations with respect to the Company’s equity incentive plans were as follows: Years Ended December 31, 2021 2020 Selling, general and administrative $ 1,154,000 $ 1,461,190 Research and development 141,281 106,267 Cost of product and product-related services revenue 22,074 17,328 $ 1,317,355 $ 1,584,785 The following table summarizes stock option activity during the two-year period ended December 31, 2021: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at January 1, 2020 193,660 $ 35.55 8.0 $ 781 Granted 387,178 7.81 Exercised - - $ - Forfeited (67,369 ) 12.99 Expired/Cancelled (26,242 ) 32.04 Balance at December 31, 2020 487,227 $ 16.78 8.6 $ 1,536 Granted 153,833 5.45 Exercised (75 ) 4.35 $ 107 Forfeited (52,874 ) 11.98 Expired/Cancelled (28,775 ) 20.39 Balance at December 31, 2021 559,336 $ 13.93 8.2 $ 30,267 Exercisable at December 31, 2020 187,031 $ 27.07 7.5 $ 305 Exercisable at December 31, 2021 298,987 $ 20.14 7.4 $ 6,269 The weighted-average fair value of stock options granted was $4.38 and $6.40 for the years ended December 31, 2021 and 2020, respectively. The 2020 stock option activity includes no Inducement Awards granted during the year ended December 31, 2020 compared with 110,000 Inducement Awards granted during the year ended December 31, 2021. As of December 31, 2021, total unrecognized compensation cost related to non-vested stock options was approximately $1.3 million, which is expected to be recognized over approximately 2.52 years. The fair value of each stock option granted has been determined using the Black-Scholes option pricing model. The material factors incorporated in the Black-Scholes model in estimating the fair value of the stock options granted for the periods presented were as follows: 2021 2020 Fair value of common stock on grant date $4.07 - 6.25 $4.35 - 11.25 Risk-free interest rate 0.85% - 1.20% 0.34% - 1.65% Expected volatility 104.2% - 107.3% 109.1% - 149.9% Expected term 5.2 to 6.1 years 5.4 to 5.9 years Expected dividend yield 0% 0% • Expected stock price volatility • Risk-free interest rate • Expected term • Expected dividend yield In preparing its Black-Scholes option-pricing model fair value calculations, the Company does not estimate a forfeiture rate to calculate stock-based compensation. The Company uses judgment in evaluating the expected volatility and expected terms utilized for the Company’s stock-based compensation calculations on a prospective basis. The following table summarizes RSU activity during the two-year period ended December 31, 2021: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at January 1, 2020 14,916 $ 43.65 Granted 7,000 7.83 Released (7,911 ) 35.85 Forfeited (1,791 ) 41.23 Balance at December 31, 2020 12,214 $ 28.61 Granted 30,000 5.20 Released (4,529 ) 29.13 Forfeited (6,508 ) 24.18 Balance at December 31, 2021 31,177 $ 6.93 Vested and unissued at December 31, 2021 4,148 $ 9.60 The weighted-average fair value of RSUs granted was $5.20 and $7.83 for the years ended December 31, 2021 and 2020, respectively. The 2020 RSU award activity includes no Inducement Awards granted during the year ended December 31, 2020 compared with 30,000 Inducement Awards granted during the year ended December 31, 2021. As of December 31, 2021, total unrecognized compensation cost related to non-vested RSUs was approximately $0.2 million, which is expected to be recognized over approximately 1.47 years. Vested and unissued awards at December 31, 2021 represents RSU awards granted in August 2018 November 2021 January 2022 2014 Employee Stock Purchase Plan In April 2015, the Company’s stockholders approved the 2014 Employee Stock Purchase Plan (the “2014 ESPP), which became effective in May 2015. Under the 2014 ESPP, the number of shares of common stock reserved for issuance automatically increased on January 1 of each calendar year, from January 1, 2016 to January 1, 2021 by the lesser of (i) 1% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, (ii) 13,000 shares, or (iii) a number determined by the Company’s Board of Directors that is less than (i) and (ii). The 2014 ESPP enables participants to contribute up to 15% of such participant’s eligible compensation during a defined period (not to exceed 27 months) to purchase common stock of the Company. The purchase price of common stock under the 2014 ESPP is the lesser of: (i) 85% of the fair market value of a share of the Company’s common stock on the first day of an offering or (ii) 85% of the fair market value of the Company’s common stock at the applicable purchase date. In August 2021, the Company’s stockholders, upon the recommendation of the Company’s Board of Directors, approved the Amended and Restated 2014 Employee Stock Purchase Plan (the “Amended 2014 ESPP”). Upon approval of the Amended 2014 ESPP, 500,000 shares of the Company’s common stock were reserved for issuance under the Amended 2014 ESPP in addition to 24,285 shares of the Company’s common stock reserved for issuance under the original 2014 ESPP. The Amended 2014 ESPP does not contain an evergreen provision all other provisions of the 2014 ESPP remained unchanged. Amounts recognized in the consolidated statements of operations with respect to the Amended 2014 ESPP were as follows: Years Ended December 31, 2021 2020 Selling, general and administrative $ 34,219 $ 12,106 Research and development 11,643 5,248 Cost of product and product-related services revenue 11,807 3,832 $ 57,669 $ 21,186 During the year ended December 31, 2021, employees purchased the following shares at the end of each of the six-month purchase periods: June 2021 December 2021 Number of Shares Price per Share Number of Shares Price per Share Total number of shares purchased 13,637 $ 3.92 20,326 $ 3.56 During the year ended December 31, 2020, employees entering the plan at various times throughout the offering period purchased the following shares at the end of each of the six-month purchase periods: June 2020 December 2020 Number of Shares Price per Share Number of Shares Price per Share ESPP Group: Group A 3,033 $ 8.29 2,857 $ 4.87 Group B - N/A 396 4.87 Total number of shares purchased 3,033 3,253 As of December 31, 2021, approximately 503,959 shares of the Company’s common stock were reserved for future issuance under the Amended 2014 ESPP. The Company recognizes employee stock purchase plan expense based on the fair value of stock purchase rights, estimated for each six-month purchase period using the Black-Scholes option pricing model. The model requires the Company to make subjective assumptions, including expected stock price volatility, risk free rate of return and estimated life. The fair value of equity-based awards is amortized straight-line over the vesting period of the award. The material factors incorporated in the Black-Scholes model in estimating the fair value of employee stock purchase plan stock purchase rights for the periods presented were as follows: 2021 2020 Fair value of common stock $4.67 - 5.85 $8.70 - 9.75 Risk-free interest rate 0.04% - 0.08% 0.18% - 1.58% Expected volatility 71.9% - 89.2% 65.8% - 88.9% Expected term 0.5 years 0.5 years Expected dividend yield 0% 0% • Fair value of common stock • Expected stock price volatility • Risk-free interest rate • Expected term • Expected dividend yield Stock Purchase Plan In December 2015, the Board of Directors adopted a Stock Purchase Plan (the “Purchase Plan”) which allows directors, any individual deemed by the Board of Directors to be an officer for purposes of Section 16 of the Exchange Act, and anyone designated by the Board of Directors as eligible to participate in the Purchase Plan to purchase shares of the Company’s common stock from the Company at fair market value. The aggregate number of shares of common stock that may be issued under the Purchase Plan shall not exceed 16,666 shares of common stock, and a maximum of 500 shares of common stock may be purchased by any one participant on any one purchase date. The Board of Directors or an authorized committee must review and approve each individual request to purchase common stock under the Purchase Plan. No stock was sold under the Purchase Plan during the years ended December 31, 2021 and 2020. As of December 31, 2021, there were 11,658 shares available for issuance under the Purchase Plan.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Commitments and Contingencies	Note 15. Commitments and Contingencies Legal Matters The Company’s industry is characterized by frequent claims and litigation, including claims regarding intellectual property and product liability. As a result, the Company may be subject to various legal proceedings from time to time. The results of any current or future litigation cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources, and other factors. Any current litigation is considered immaterial and counter claims have been assessed as remote. Employee Agreements The Company has entered into Severance and Change in Control Plan agreements with certain named executive officers and various other members of management, which provide salary continuation payments, bonuses and, in certain instances, the acceleration of the vesting of certain equity awards to individuals in the event that the individual is terminated other than for cause, as defined in the applicable agreement. Indemnification Agreements In the course of operating its business, the Company has entered into, and continues to enter into, separate indemnification agreements with the Company’s directors and executive officers, in addition to the indemnification provided for in the Company’s amended and restated bylaws. These agreements may require the Company to indemnify its directors and executive officers for certain expenses incurred in any action or proceeding arising out of their services as one of the Company’s directors or executive officers. Product Warranty The following is a summary of the Company’s general product warranty liability. Product warranty liabilities of approximately $97,000 and $23,000 were included in accrued liabilities and other non-current liabilities, respectively, in the accompanying consolidated balance sheets as of December 31, 2021. Expense relating to the recording of this reserve is recorded in cost of product and product-related services revenue within the accompanying consolidated statements of operations. Years Ended December 31, 2021 2020 Beginning balance $ 92,696 $ 94,482 Cost of warranty claims (166,641 ) (32,866 ) Increase in warranty reserve 194,330 31,080 Ending balance $ 120,385 $ 92,696 Defined Contribution Plan In January 2003, the Company established a defined contribution plan (“401(k) Plan”) under section 401(k) of the Internal Revenue Code of 1986, as amended (the “IRC”). All employees who are over the age of 21 and who are expected to work at least 1,000 hours in a calendar year are eligible for participation in the 401(k) Plan upon commencement of employment with the Company. The Company may make discretionary contributions to the 401(k) Plan but has not done so during the years ended December 31, 2021 and 2020.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Income Taxes	Note 16. Income Taxes The Company provides for income taxes based upon management’s estimate of taxable income or loss for each respective period. The Company recognizes an asset or liability for the deferred tax consequences of temporary differences between the tax bases of assets and liabilities and their reported amounts in the financial statements. These temporary differences would result in deductible or taxable amounts in future years, when the reported amounts of the assets are recovered or liabilities are settled, respectively. In each period since inception, the Company has recorded a valuation allowance for the full amount of its net deferred tax assets, as the realization of the net deferred tax assets is uncertain. As a result, the Company has not recorded any federal or state income tax benefit in the accompanying consolidated statements of operations; however, income tax expense has been recorded for state minimum and foreign income taxes. The Company periodically reviews its filing positions for all open tax years in all U.S. federal, state and international jurisdictions where the Company is or might be required to file tax returns or other required reports. The Company applies a two-step approach to recognizing and measuring uncertain tax positions. The Company evaluates the tax position for recognition by determining if the weight of available evidence indicates that it is “more likely than not” that the position will be sustained on audit, including resolution of related appeals or litigation process, if any. The term “more likely than not” means a likelihood of more than 50 percent. If the tax position is not more likely than not to be sustained in a court of last resort, the Company may not recognize any of the potential tax benefit associated with the position. The Company recognizes a benefit for a tax position that meets the more likely than not criterion at the largest amount of tax benefit that is greater than 50 percent likely of being realized upon its effective resolution. Unrecognized tax benefits involve management’s judgment regarding the likelihood of the benefit being sustained. The final resolution of uncertain tax positions could result in adjustments to recorded amounts and may affect the Company’s results of operations, financial position and cash flows. As discussed below, the Company has estimated $3.2 million and $3.0 million of uncertain tax positions as of December 31, 2021 and 2020, respectively, related to certain tax credit carryforwards. The Company’s policy is to recognize interest and/or penalties related to income tax matters in income tax expense. The Company had no accrual for interest or penalties at December 31, 2021 or 2020, and has not recognized interest or penalties during the years ended December 31, 2021 and 2020, since there was no reduction in income taxes paid due to uncertain tax positions. Management of the Company believes no significant change to the amount of unrecognized tax benefits will occur within the next 12 months. The following table summarizes loss before income taxes: Years Ended December 31, 2021 2020 U.S. pre-tax loss $ (17,156,070 ) $ (20,855,184 ) Foreign pre-tax gain (loss) 33,375 (619 ) Loss before income taxes $ (17,122,695 ) $ (20,855,803 ) The components of income tax expense are as follows: Years Ended December 31, 2021 2020 Current: Federal $ — $ — State 13,769 10,860 Foreign 8,706 3,555 Total current income tax expense $ 22,475 $ 14,415 Deferred: Federal $ — $ — State — — Foreign — — Total deferred income tax expense $ — $ — Total income tax expense $ 22,475 $ 14,415 The Company’s actual income tax expense for the years ended December 31, 2021 and 2020 differ from the expected amount computed by applying the statutory federal income tax rate to loss before income taxes as follows: Years Ended December 31, 2021 2020 Computed tax (benefit) at 21% $ (3,586,925 ) $ (4,379,719 ) State taxes, net of federal benefit (1,177,951 ) (832,055 ) Stock-based compensation 240,177 310,811 Foreign tax rate differential (2,171 ) 3,685 Return to provision 53,340 26,120 Nontaxable loan forgiveness (360,570 ) — Other 9,048 31,850 Research and development tax credit - state (265,362 ) (218,991 ) Research and development tax credit - federal (212,408 ) (197,836 ) Uncertain tax position adjustment for prior periods (6,395 ) (5,694 ) Increase in valuation allowance 5,331,692 5,276,244 $ 22,475 $ 14,415 Deferred tax assets and liabilities comprise the following: Years Ended December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 47,752,053 $ 43,308,483 Research and development credits 3,940,199 3,475,341 Deferred revenue 42,802 50,429 Inventory reserve 6,806 6,653 Fixed assets and intangibles 304,019 313,117 Accrued NuvoGen liability 1,196,563 1,274,896 Lease liability 366,653 269,147 Other 711,343 211,574 Gross deferred tax assets 54,320,438 48,909,640 Valuation allowance (53,958,617 ) (48,626,925 ) Deferred tax assets, net 361,821 282,715 Deferred tax liabilities: Right of use asset 361,821 257,705 Other — 25,010 Total deferred tax liabilities 361,821 282,715 Net deferred tax assets (liabilities) $ - $ - As of December 31, 2021, the Company has estimated federal and state net operating loss (“NOL”) carryforwards of approximately $194.0 million and $125.6 million for federal and state income tax purposes, respectively. $121.8 million of the federal NOLs are scheduled to expire from 2023 through , while the remaining NOLs do not expire. $124.6 million of the state NOLs are scheduled to expire from 2024 through 2041, while the remaining NOLs do not expire. The Company’s federal and state tax credit carryforwards begin expiring For financial reporting purposes, valuation allowances of $54.0 million and $48.6 million at December 31, 2021 and 2020, respectively, have been established to offset deferred tax assets relating primarily to NOLs and research and development credits. The increase in the valuation allowance of $5.3 million for the year ended December 31, 2021 was primarily due to increased operating losses. The Company has established a valuation allowance against its entire net deferred tax asset. As a result, the Company does not recognize any tax benefit until it is in a taxpaying position or there is no longer negative evidence leading to the conclusion that it is more likely than not that the benefits will not be realized. Pursuant to Sections 382 and 383 of the IRC, annual use of the Company’s NOLs and research and development credit carryforwards may be limited if there is a cumulative change in ownership of greater than 50% within a three-year A reconciliation of the Company’s gross unrecognized tax benefits is as follows: Years Ended December 31, 2021 2020 Balance at beginning of year $ 2,960,842 $ 2,731,015 Increases to prior positions — — Decreases to prior positions (6,395 ) (5,694 ) Increases for current year positions 238,884 235,521 Balance at end of year $ 3,193,331 $ 2,960,842 As of December 31, 2021, the Company had $3.2 million of gross unrecognized tax benefits, related to research and experimental tax credits. The Company had no unrecognized tax benefits as of December 31, 2021, which, if recognized, would affect the annual effective tax rate, due to the full valuation allowance on the deferred tax assets. Although it is possible that the amount of unrecognized benefits with respect to our uncertain tax positions will increase or decrease in the next twelve months, the Company does not expect material changes. The CARES Act contained certain income tax relief provisions, including a modification to the limitation of business interest expense for tax years beginning in 2019 and 2020. In addition, the CARES Act permitted NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021, and allowed NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The Company did not experience any material impacts to its tax status or reporting as a result of these provisions. The Company files income tax returns in the United States, Arizona, California, Texas, various other state jurisdictions, and France ,

Subsequent Events

Subsequent Events	12 Months Ended
	Dec. 31, 2021
Subsequent Events [Abstract]
Subsequent Events	Note 17. Subsequent Events On March 21, 2022, pursuant to a Securities Purchase Agreement (the “March 2022 Purchase Agreement”) with a single investor the Company issued and sold to the investor 3,244,987 units at a price of $2.312 per unit (less $0.001 for each pre-funded warrant purchased in lieu of a share of common stock) for gross proceeds to the Company, before deducting the placement agent fees and other estimated fees and expenses, of approximately $7.5 million. Each unit consisted of one share of common stock (or one pre-funded warrant in lieu thereof), a common warrant to purchase one share of the Company’s common stock with a term of 24 months from the issuance date, and a common warrant to purchase one share of the Company’s common stock with a term of 66 months from the issuance date. Each of the common warrants is exercisable six months following the closing date, and has an exercise price of $2.062 per share. Each pre-funded warrant has an exercise price of $0.001 per share and does not expire until exercised in full. The securities sold under the March 2022 Purchase Agreement have not been registered under the Securities Act or any state securities laws. The Company has agreed to file a resale registration statement with the SEC for purposes of registering the resale of the shares of common stock issued and issuable pursuant to the March 2022 Purchase Agreement within 10 days following the filing of this Annual Report on Form 10-K.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
COVID-19 Pandemic	COVID-19 Pandemic The full impact of the COVID-19 pandemic continues to evolve as of the date of this report and management continues to actively monitor the potential impact of the global situation on its financial condition, liquidity, operations, suppliers, industry and workforce. Given the ongoing evolution of the COVID-19 pandemic, including resurgences in many areas of the world and the global responses to curb its spread, the Company is not able to fully estimate the effects of the COVID-19 pandemic on its results of operations, financial condition or liquidity. The Company experienced a significant slowing of product and product-related services revenue generation beginning in March 2020 and believes that while it has seen some recovery, this impact will continue to be seen at some level at least through the first half of 2022. The extent of this impact varied from customer to customer depending upon how they have been directly or indirectly impacted by local stay-at-home orders and other social distancing measures, prioritization by those customers as the immediate impacts of the pandemic have passed, and the workforce and supplier impacts that each customer has experienced during the pandemic. The Company has not experienced delays in its development efforts because of stay-at-home orders despite its efforts to prioritize the safety of its employees during this pandemic. In addition, the impact of the COVID-19 pandemic on the Company’s ability to source raw materials and other supplies has not been significant to date. However, a change in or loss of suppliers or other supply chain or distribution network partners due to the ongoing impacts of the pandemic on the global economy could adversely affect the Company’s business and the businesses of its vendors, partners and customers, and could result in future reductions in sales and operating results. While there remains uncertainty as to the ultimate impact of the COVID-19 pandemic, the Company has considered the known impacts on its business as of the date these consolidated financial statements were issued and has reflected any known or expected impacts in its consolidated financial statements, including consideration of potential impairment risks to its long-lived assets, potential accounts receivable collection risks and potential impacts to its overall liquidity position. COVID-19 Related Credits and Relief In March 2020, the Coronavirus Aid, Relief, and Economic Security Act (the “CARES Act”) was enacted in response to COVID‑19. On April 21, 2020, the Company received proceeds from a loan pursuant to the Paycheck Protection Program (“PPP”) of the CARES Act (the “PPP Loan”) in the amount of $1.7 million from SVB, as lender (see Note 8). There is no guidance in U.S. GAAP that specifically addresses the accounting by a business entity that obtains a forgivable loan from a government entity. Notwithstanding the absence of specific guidance in U.S. GAAP and given the significant uncertainties related to whether many entities that received loans are qualified for a PPP Loan and would meet the conditions for loan forgiveness, the Company accounted for the PPP Loan as debt in accordance with FASB, ASC 470, Debt In December 2020, the Consolidated Appropriations Act (the “Appropriations Act”) was signed into law to further address the ongoing impacts of COVID-19. The Appropriations Act introduced several additional potential credits and benefits for employers to consider applying for, including, but not limited to, the ability for employers who have previously obtained a PPP Loan to potentially also qualify for Employee Retention Credits (“ERC”), initially created as part of the CARES Act. The ERC provided a per employee credit to eligible businesses based on a percentage of qualified wages and health insurance benefits paid to employees. The benefit was provided as a refundable payroll tax credit claimed quarterly as a reduction to payroll taxes or cash refunds. The initial credit available was equal to 50% of qualified wages paid to employees during a quarter, capped at $10,000 of qualified wages per employee through December 31, 2021. In March 2021, the American Rescue Plan of 2021 was enacted to, amongst other things, extend and expand ERC benefits through December 31, 2021. In accordance with these additional relief provisions, the tax credit was increased to 70% of qualified wages paid to employees during a quarter, and the limit on qualified wages per employee was increased to $10,000 of qualified wages per quarter. In November 2021, the Infrastructure Investment and Jobs Act was signed into law and ends the employee retention credit early, making wages paid after September 30, 2021, ineligible for the credit. The Company qualified for certain ERC benefits during the years ended December 31, 2021 and 2020. As there is no guidance in U.S. GAAP that specifically addresses the accounting for the receipt of government assistance similar to the ERC, the Company considered two primary approaches in accounting for the ERC. The first was as government grants, by reference to ASC 958-605, Not-for-Profit-Entities Revenue Recognition, and the other by reference to IAS 20, Accounting for Government Grants and Disclosure of Government Assistance. With reference to IAS 20, the Company considered the following: (1) Under this model, the Company would not recognize government assistance until reasonably sure any conditions attached to the assistance would be met, and the Company would in fact receive the funds. (2) Once the Company was reasonably certain the conditions were met, the Company would then record the earnings impact of the grants over the periods in which the Company recognizes the costs the grants are intended to pay for. These costs should be recognized as expenses. (3) The funds could be recorded as other income or as an offset to related qualifying expenses. The Company has historically offset actual expenses that are reimbursed within the applicable expense line. Because the ERC was intended to reimburse the Company for actual costs incurred during the given period or quarter, the Company determined that it was most reasonable to account for these credits as an offset to the qualifying payroll expenses. ERC benefits of approximately $1.7 million and $0.5 million were included in operating expenses as an offset to the related compensation costs in the accompanying consolidated statements of operations for the years ended December 31, 2021 and 2020, respectively, as follows: Years Ended December 31, 2021 2020 Cost of product and product-related services revenue $ 467,481 $ 108,714 Selling, general and administrative 795,650 229,025 Research and development 444,888 135,744 $ 1,708,019 $ 473,483 ERC benefits receivable of $0.4 million and $0.5 million were included in prepaid expenses and other in the accompanying consolidated balance sheets as of December 31, 2021 and 2020, respectively. The Company has also applied the guidance in ASU No. 2021-10, Government Assistance (Topic 832): Disclosures by Business Entities about Government Assistance Laws and regulations concerning government programs, including the ERC and PPP Loan, are complex and subject to varying interpretations. Claims made under these programs may also be subject to retroactive audit and review. While we do not believe there is a basis for estimation of an audit or recapture risk at this time, there can be no assurance that regulatory authorities will not challenge the Company’s claim to the ERC or PPP Loan in a future period.
Basis of Presentation	Basis of Presentation The consolidated financial statements and accompanying notes were prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”). In November 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen shares of issued and outstanding common stock were exchanged for one share of common stock. All share and per share amounts within the consolidated financial statements and notes thereto have been adjusted to reflect the reverse stock split for all periods and dates presented. See Note 14 for more information about the Company’s reverse stock split.
Principles of Consolidation	Principles of Consolidation The Company formed a French subsidiary, HTG Molecular Diagnostics France SARL, in November 2018. The consolidated financial statements include the accounts of the Company and this wholly owned subsidiary after elimination of intercompany transactions and balances as of December 31, 2021 and 2020.
Going Concern and Liquidity	Going Concern and Management has assessed the Company’s ability to continue as a going concern within one year of issuance of these consolidated financial statements. The accompanying consolidated financial statements have been prepared assuming that the Company will continue as a going concern, which contemplates the realization of the assets and satisfaction of liabilities in the normal course of business. However, the Company has had recurring operating losses and negative operating cash flows since its inception and has an accumulated deficit of $208.3 million as of December 31, 2021. As of December 31, 2021, the Company had working capital of $17.2 million and long-term liabilities of $10.1 million. The Company’s liability balances consist primarily of its debt obligations, including an asset-secured loan with Silicon Valley Bank (“SVB”) (the “SVB Term Loan”) (see Note 8), as well as an obligation to NuvoGen Research, LLC (the “NuvoGen obligation”) (see Note 10). Potentially changing circumstances, including COVID-19 uncertainties, may result in the depletion of the Company’s capital resources more rapidly than it currently anticipates, resulting in the Company not having adequate resources to fund its planned operations and expenditures for at least the next 12 months and to comply with the financial covenant in the Loan and Security Agreement for the SVB Term Loan (the “Loan Agreement”). These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. The accompanying consolidated financial statements do not include any adjustments that may result from the outcome of these uncertainties. The Company will need to raise additional capital to fund its operations and service its long-term debt obligations until its revenue reaches a level sufficient to provide for self-sustaining cash flows. There can be no assurance that additional capital will be available on acceptable terms, or at all, or that the Company’s revenue will reach a level sufficient to provide for self-sustaining cash flows. In addition, the Company must comply with a financial covenant in the Loan Agreement requiring the Company to maintain unrestricted cash, including short term available-for-sale securities, of not less than the greater of (i) $12.5 million and (ii) an amount equal to six times the amount of the Company’s average monthly Cash Burn (as defined in the Loan Agreement) over the trailing three months.
Use of Estimates	Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The Company’s estimates include revenue recognition, stock-based compensation expense, bonus and warranty accrual, income tax valuation allowances and reserves, recovery of long‑lived assets, lease liability, inventory obsolescence and valuation of inventory, accounts receivable, allowance for doubtful accounts and available-for-sale securities. Actual results could materially differ from those estimates, especially in light of the significant uncertainty that remains as to the full impact of COVID-19 on the Company’s operations, as well as those of its workforce, supply chains, distribution networks and those of its customers.
Cash and Cash Equivalents	Cash and Cash Equivalents The Company considers all highly liquid investments with an original maturity of three months or less to be cash equivalents. Cash and cash equivalents consist of cash on deposit with financial institutions, commercial paper, money market instruments and high credit quality corporate debt securities purchased with a term of three months or less.
Accounts Receivable	Accounts Receivable Accounts receivable represent valid claims against debtors. Management reviews accounts receivable regularly to determine, using the specific identification method, if any receivable amounts will potentially be uncollectible and to estimate the amount of allowance for doubtful accounts necessary to reduce accounts receivable to its estimated net realizable value.
Investments in Available-for-Sale Securities	Investments in Available-for-Sale Securities The Company classifies its debt securities, which are reported at estimated fair value with unrealized gains and losses included in accumulated other comprehensive loss, net of tax, as available-for-sale securities. Investments in securities with maturities of less than one year, or where management’s intent is to use the investments to fund current operations, or to make them available for current operations, are classified as short-term investments. Realized gains, realized losses and declines in value of securities judged to be other-than-temporary, are included in other income (expense) within the consolidated statements of operations. The cost of investments for purposes of computing realized and unrealized gains and losses is based on the specific identification method. Interest earned on securities is also included in other income (expense) within the consolidated statements of operations. The Company recognizes other-than-temporary impairment (“OTTI”) of a debt security for which there has been a decline in fair value below amortized cost if (i) management intends to sell the security, (ii) it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis, or (iii) the Company does not expect to recover the entire amortized cost basis of the security. The amount by which amortized cost exceeds the fair value of a debt security that is considered to have OTTI is separated into a component representing the credit loss, which is recognized in earnings, and a component related to all other factors, which is recognized in other comprehensive income (loss). The measurement of the credit loss component is equal to the difference between the debt security’s amortized cost basis and the present value of its expected future cash flows discounted at the security’s effective yield. If the Company intends to sell the security, or if it is more likely than not it will be required to sell the security before recovery, an OTTI write-down is recognized in earnings equal to the entire difference between the amortized cost basis and fair value of the security .
Fair Value of Financial Instruments	Fair Value of Financial Instruments Fair value measurements are based on the premise that fair value is an exit price representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As such, fair value is a market-based measurement that should be determined based on assumptions that market participants would use in pricing an asset or liability. As a basis for considering such assumptions, the following three-tier fair value hierarchy has been used in determining the inputs used in measuring fair value: Level 1 – Quoted prices in active markets for identical assets or liabilities on the reporting date. Level 2 – Pricing inputs are based on quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. Level 3 – Pricing inputs are generally unobservable and include situations where there is little, if any, market activity for the investment. The inputs into the determination of fair value require management’s judgment or estimation of assumptions that market participants would use in pricing the assets or liabilities. The fair values are therefore determined using factors that involve considerable judgment and interpretations, including but not limited to private and public comparables, third-party appraisals, discounted cash flow models, and fund manager estimates. The carrying value of financial instruments classified as current assets and current liabilities approximate fair value due to their liquidity and short-term nature. Investments that are classified as available-for-sale are recorded at fair value, which is determined using quoted market prices, broker or dealer quotations or alternative pricing sources with reasonable levels of price transparency. The carrying value of the SVB Term Loan (see Note 8) is estimated to approximate its fair value as the interest rate approximates the market rate for debt with similar terms and risk characteristics. The NuvoGen obligation relates to an asset purchase transaction with a then-common stockholder of the Company (see Note 10). As of December 31, 2021, the estimated aggregate fair value of the NuvoGen obligation is approximately $4.6 million, determined using a Monte Carlo simulation with key assumptions including future revenue, volatility, discount and risk-free rates. The estimated fair value of the NuvoGen obligation represents a Level 3 measurement.
Inventory	Inventory Inventory, consisting of raw materials, work in process and finished goods, is stated at the lower of cost (first-in, first-out) or net realizable value. Cost is determined using a standard cost system, whereby the standard costs are updated periodically to reflect current costs. Net realizable value is the estimated selling price in the ordinary course of business less reasonably predictable costs of completion and disposal. The Company reserves or writes down its inventory for estimated obsolescence or inventory in excess of reasonably expected near term sales or unmarketable inventory, in an amount equal to the difference between the cost of inventory and the estimated market value, based upon assumptions about future demand and market conditions. If actual market conditions are less favorable than those projected by the Company, additional inventory write-downs may be required. Inventory impairment charges establish a new cost basis for inventory and charges are not reversed subsequently to income, even if circumstances later suggest that increased carrying amounts are recoverable. The Company classifies inventory as long-term when the Company expects to utilize the inventory beyond its normal operating cycle. Equipment that is under evaluation for purchase remains in inventory as the Company maintains title to the equipment throughout the evaluation period. The period of time customers use to evaluate the Company’s equipment generally ranges from 90 to 180 days, and in certain circumstances the evaluation period may need to be extended beyond that period. However, in no case will the evaluation period exceed one year. If the customer has not purchased the equipment or entered into a reagent rental agreement with the Company after evaluating the product for one year, the equipment is returned to the Company or the customer is allowed to continue use of the equipment, in which case the equipment is written off to selling, general and administrative expense in the consolidated statements of operations. HTG EdgeSeq instruments at customer locations under evaluation agreements are included in finished goods inventory. Finished goods inventory under evaluation as of December 31, 2021 was $204,638 compared with $50,855 as of December 31, 2020.
Property and Equipment	Property and Equipment Property and equipment are stated at historical cost and depreciated over their useful lives, which range from three to five years, using the straight-line method. Equipment used in the field is amortized using the straight-line method over the lesser of the period of the related reagent rental or collaborative development services agreement where applicable or the estimated useful life. Leasehold improvements are amortized using the straight-line method over the lesser of the remaining lease term or the estimated useful life. Costs incurred in the development and installation of software for internal use and in the development of the Company’s website are expensed or capitalized, depending on whether they are incurred in the preliminary project stage (expensed), application development stage (capitalized), or post-implementation stage (expensed). Amounts capitalized following project completion are amortized on a straight-line basis over the useful life of the developed asset, which is generally three years. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of the asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of an asset group to the estimated undiscounted future cash flows expected to be generated by the asset group. If the carrying amount of an asset group exceeds its estimated future cash flow, an impairment charge is recognized in the amount by which the carrying amount of the asset group exceeds the fair value of the asset group. Although the Company has accumulated losses since inception, the Company believes the future cash flows will be sufficient to exceed the carrying value of the Company’s long-lived assets. There were no impairments of long-lived assets during the years ended December 31, 2021 and 2020.
Leases	Leases Arrangements meeting the definition of a lease are classified as operating or financing leases and are recorded on the consolidated balance sheets as both a right-of-use asset and a lease liability for each type of lease, calculated by discounting fixed lease payments over the lease term at the rate implicit in the lease or the Company’s incremental borrowing rate. Lease liabilities are increased by interest and reduced by payments each period, and the right-of-use asset is amortized over the lease term. For operating leases, interest on the lease liability and the amortization of the right-of-use asset result in straight-line rent expense over the lease term. For financing leases, interest on the lease liability and the amortization of the right-of-use asset results in front-loaded expense over the lease term. Variable lease expenses are recorded to rent expense as incurred. In calculating the right-of-use asset and lease liability, the Company elects to combine lease and non-lease components for all classes of assets currently under lease, including facilities and computer equipment. The Company excludes short-term leases having initial terms of 12 months or less as an accounting policy election and recognizes rent expense on short-term leases on a straight-line basis over the lease term for these leases.
Debt Issuance Costs and Debt Discounts	Debt Issuance Costs and Debt Discounts Costs incurred to issue non-revolving debt instruments are recognized as a reduction to the related debt balance in the consolidated balance sheets and amortized to interest expense over the contractual term of the related debt using the effective interest method. Costs incurred to issue the Loan Agreement with SVB were deferred as an asset in the consolidated balance sheets and are being amortized on a straight-line basis to interest expense over the term of the loan. Cost incurred to issue the MidCap Credit and Security Agreement (Revolving Loan) under the Company’s credit facility with MidCap Financial Trust (the “MidCap Credit Facility”) were deferred as an asset in the consolidated balance sheets and amortized on a straight-line basis to interest expense over the term of the revolving commitment until extinguishment of the MidCap Credit Facility in June 2020 (see Note 8) .
Contract Liabilities	Contract Liabilities Contract liabilities represent cash receipts for products or services to be delivered in future periods, including up-front fees received relating to custom research use only (“RUO”) assay design and collaborative development services. When products or services are delivered to customers, contract liabilities are recognized as earned. Up-front fees received for custom RUO assay design or collaborative development services are recognized over time based on the costs incurred to date compared with total expected costs as design or development procedures are completed and outputs are produced.
Revenue Recognition	Revenue Recognition The Company accounts for its revenue in accordance with Financial Accounting Standards Board (“FASB”), Accounting Standards Codification (“ASC”) 606, Revenue from Contracts with Customers Collaborative Arrangements For contracts where the period between when the Company transfers a promised good or service to the customer and when the customer pays is one year or less, the Company has elected the practical expedient to not adjust the promised amount of consideration for the effects of a significant financing component. The Company has made a policy election to exclude from the measurement of the transaction price all taxes assessed by a government authority that are both imposed on and concurrent with a specific revenue producing transaction and collected by the Company from a customer. Such taxes may include but are not limited to sales, use, value added and certain excise taxes. See Note 9 for additional discussion of the Company’s revenue recognition policies.
Product Warranty	Product Warranty The Company generally provides a one-year warranty on its HTG EdgeSeq platform covering the performance of system hardware and software in conformance with customer specifications under normal use and protecting against defects in materials and workmanship. The Company may, at its option, replace, repair or exchange products covered under valid warranty claims. A provision for estimated warranty costs is recognized at the time of sale, through cost of product and product-related services revenue, based upon recent historical experience and other relevant information as it becomes available. Customers have the option to purchase an extended warranty after the one-year warranty period expires. The Company continuously assesses the adequacy of its product warranty accrual by reviewing actual claims and adjusts the provision as needed. Warranty accrual is included in accrued liabilities and other non-current liabilities in the consolidated balance sheets.
Research and Development Expenses	Research and Development Expenses Research and development expenses represent costs incurred internally for and externally in support of research and development activities. These costs include those generated through research and development efforts for the improvement and expansion of the Company’s proprietary technology and product offerings, including the technology related to the Company’s HTG Therapeutics business units, costs to continue improving and expanding the utility of the HTG EdgeSeq technology, as well as those related to third-party collaborative development agreements, for which related revenue is included in collaborative development services revenue in the consolidated statements of operations. There were no costs associated with collaborative development services included in research and development expense in the consolidated statements of operations for the year ended December 31, 2021.
Stock-based Compensation	Stock-based Compensation The Company incurs stock-based compensation expense relating to grants of restricted stock units (“RSUs”) and stock options to employees, consultants and non-employee directors under its equity incentive plans, and stock purchase rights granted under its employee stock purchase plans. The Company recognizes expense for stock-based awards based on the fair value of awards on the date of grant. The fair value of RSUs is based on the quoted market price of the Company’s common stock on the date of grant. The fair value of stock purchase rights and stock options granted pursuant to the Company’s equity incentive plans is estimated on the date of grant using the Black-Scholes option pricing model. The determination of the fair value utilizing the Black-Scholes option pricing model is affected by the fair value of the Company’s stock price and several assumptions, including volatility, expected term, risk-free interest rate, and dividend yield. Generally, these assumptions are based on historical information and judgment is required to determine if historical trends may be indicators of future outcomes. The Company accounts for forfeitures as they occur.
Income Taxes	Income Taxes The Company accounts for income taxes under the asset and liability method. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to the differences between the financial statement carrying amounts and tax base of assets and liabilities using enacted tax rates and laws that will be in effect when the differences are expected to reverse. A valuation allowance is established against net deferred tax assets for the uncertainty it presents of our ability to use the net deferred tax assets, in this case, primarily carryforwards of net operating tax losses and research and development tax credits. In assessing the realizability of net deferred tax assets we have assessed the likelihood that net deferred tax assets will be recovered from future taxable income, and to the extent that it is “more likely than not” that the assets will not be recovered or there is an insufficient history of operating profits, a valuation allowance is established. We record the valuation allowance in the period we determine that it is more likely than not that net deferred tax assets will not be realized. For the years ended December 31, 2021 and 2020, we have provided a full valuation allowance for all net deferred tax assets due to their current realization being considered remote in the near term. Uncertain tax positions taken or expected to be taken in a tax return are accounted for using the more likely than not threshold for financial statement recognition and measurement. Therefore, for income tax positions where it is not more likely than not that a tax benefit will be sustained in a court of last resort, the Company does not recognize a tax benefit in its financial statements.
Foreign Currency Translation and Foreign Currency Transactions	Foreign Currency Translation and Foreign Currency Transactions The Company has assets and liabilities, including accounts receivable and accounts payable, which are denominated in currencies other than its functional currency. These assets and liabilities are subject to re-measurement, the impact of which is recorded in selling, general and administrative expense within the consolidated statements of operations. Adjustments resulting from translating foreign functional currency financial statements of the Company’s wholly owned subsidiary into U.S. Dollars are included in the foreign currency translation adjustment, a component of accumulated other comprehensive income (loss) in the consolidated statements of changes in stockholder’s equity.
Comprehensive Income (Loss)	Comprehensive Income (Loss) Comprehensive income (loss) includes certain changes in equity that are excluded from net loss. Specifically, unrealized gains and losses on short-term available-for-sale investments and adjustments resulting from translating foreign functional currency financial statements into U.S. Dollars are included in comprehensive loss.
Concentration Risks	Concentration Risks Financial instruments that potentially subject the Company to credit risk consist principally of cash and cash equivalents and accounts receivable. The Company maintains the majority of its cash balances in the form of cash deposits in bank checking and money market accounts in amounts in excess of federally insured limits. Management believes, based upon the quality of the financial institutions, that the credit risk with regard to these deposits is not significant. The Company sells its instruments, consumables, sample processing services, custom RUO assay design and collaborative development services primarily to biopharmaceutical companies, academic institutions and molecular labs. The Company routinely assesses the financial strength of its customers and credit losses have been minimal to date. The Company’s top two customers accounted for 20% and 10% of the Company’s total revenue for the year ended December 31, 2021, compared with the top customer accounting for 11% of the Company’s total revenue for the year ended December 31, 2020. The largest two customers accounted for approximately 18% and 17% of the Company’s accounts receivable as of December 31, 2021. The third and fourth largest customers accounted for approximately 10% each of the Company’s accounts receivable as of December 31, 2021. The largest two customers accounted for approximately 9% each of the Company’s accounts receivable as of December 31, 2020. Two vendors accounted for 28% and 16% of the Company’s accounts payable as of December 31, 2021, compared with two vendors who accounted for 21% and 20% of the Company’s accounts payable as of December 31, 2020. The Company is also subject to supply chain risks related to the reliance on a single supplier to manufacture a subcomponent used in its HTG EdgeSeq instruments. Although there are a limited number of manufacturers for components of this type, the Company believes that other suppliers could provide similar products on comparable terms. However, a change in or loss of this supplier could significantly delay the delivery of products, which in turn would materially affect the Company’s ability to generate revenue.
Recently Adopted and New Accounting Pronouncements	Recently Adopted Accounting Pronouncements In November 2021, the FASB issued ASU No. 2021-10, Government Assistance (Topic 842): Disclosures by Business Entities about Government Assistance In October 2020, the FASB issued ASC Update (“ASU”) No. 2020-10, Codification Improvements In December 2019, the FASB issued ASU No. 2019-12, Income Taxes (Topic 740): Simplifying the Accounting for Income Taxes Recent Accounting Pronouncements The following are new FASB ASUs that had not been adopted by the Company as of December 31, 2021: In August 2020, the FASB issued ASU No. 2020-06, Debt – Debt with Conversion and other Options (Subtopic 470-20) and Derivatives and Hedging – Contracts in Entity’s Own Equity (Subtopic 815-40): Accounting for Convertible Instruments and Contracts in an Entity’s Own Equity (“ASU 2020-06”), which simplifies accounting for convertible instruments by removing major separation models required under current GAAP. ASU 2020-06 removes certain settlement conditions that are required for equity contracts to qualify for the derivative scope exception and also simplifies the diluted earnings per share calculation in certain areas. The standard is effective for public business entities, excluding entities eligible to be smaller reporting companies as defined by the SEC, for fiscal years and interim periods within those fiscal years, beginning after December 15, 2021. For all other entities, the standard will be effective for fiscal years beginning after December 15, 2023. Early adoption is permitted, and adoption must be as of the beginning of the Company’s annual fiscal year. The Company is currently evaluating the impact of this standard on its consolidated financial statements and related disclosures. In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments - Credit Losses

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	12 Months Ended
	Dec. 31, 2021
Accounting Policies [Abstract]
Summary of Related Compensation Costs	ERC benefits of approximately $1.7 million and $0.5 million were included in operating expenses as an offset to the related compensation costs in the accompanying consolidated statements of operations for the years ended December 31, 2021 and 2020, respectively, as follows: Years Ended December 31, 2021 2020 Cost of product and product-related services revenue $ 467,481 $ 108,714 Selling, general and administrative 795,650 229,025 Research and development 444,888 135,744 $ 1,708,019 $ 473,483

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2021
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory, net of allowance, consisted of the following as of the date indicated: December 31, 2021 2020 Raw materials $ 1,964,407 $ 1,079,528 Work in process 312,803 147,455 Finished goods 447,145 291,195 Total gross inventory 2,724,355 1,518,178 Less inventory allowance (25,306 ) (26,052 ) $ 2,699,049 $ 1,492,126

Fair Value (Tables)

Fair Value (Tables)	12 Months Ended
	Dec. 31, 2021
Fair Value Disclosures [Abstract]
Financial Assets and Liabilities Measured at Fair Value on Recurring Basis	The following table classifies the Company’s financial assets measured at fair value on a recurring basis as of December 31, 2021 and 2020, respectively, in the fair value hierarchy: December 31, 2021 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 9,083,302 $ — $ — $ 9,083,302 Investments available-for-sale at fair value Corporate debt securities — 12,343,456 — 12,343,456 Total $ 9,083,302 $ 12,343,456 $ — $ 21,426,758 December 31, 2020 Level 1 Level 2 Level 3 Total Asset included in: Cash and cash equivalents Money market securities $ 17,497,282 $ — $ — $ 17,497,282 Corporate debt securities 4,499,270 4,499,270 Investments available-for-sale at fair value Corporate debt securities — 6,298,075 — 6,298,075 Total $ 17,497,282 $ 10,797,345 $ — $ 28,294,627

Available-for-Sale Securities (

Available-for-Sale Securities (Tables)	12 Months Ended
	Dec. 31, 2021
Investments Debt And Equity Securities [Abstract]
Summary of Available-for-sale Securities	The following is a summary of the Company’s available-for-sale securities as of December 31, 2021 and 2020: December 31, 2021 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities 12,343,456 — — 12,343,456 Total available-for-sale securities $ 12,343,456 $ — $ — $ 12,343,456 December 31, 2020 Gross Gross Fair Value Amortized Unrealized Unrealized (Net Carrying Cost Gains Losses Amount) Corporate debt securities 6,298,075 — — 6,298,075 Total available-for-sale securities $ 6,298,075 $ — $ — $ 6,298,075
Summary of Contractual Maturities of Debt Investment Securities	Contractual maturities of debt investment securities as of December 31, 2021 are shown below Under 1 Year 1 to 2 Years Total Corporate debt securities 12,343,456 — 12,343,456 Total available-for-sale securities $ 12,343,456 $ — $ 12,343,456

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2021
Property Plant And Equipment [Abstract]
Summary of Property and Equipment	Property and equipment, net consisted of the following as of the dates indicated: December 31, 2021 2020 Furniture & fixtures $ 872,877 $ 1,082,717 Leasehold improvements 1,931,762 1,943,534 Equipment used in manufacturing 2,432,242 2,166,743 Equipment used in research & development 2,343,930 2,506,644 Equipment used in the field 216,218 208,005 Software 480,740 420,301 Property and equipment 8,277,769 8,327,944 Less: accumulated depreciation and amortization (7,158,883 ) (7,100,542 ) $ 1,118,886 $ 1,227,402

Accrued Liabilities (Tables)

Accrued Liabilities (Tables)	12 Months Ended
	Dec. 31, 2021
Accrued Liabilities Current [Abstract]
Summary of Accrued Liabilities	Accrued liabilities consisted of the following as of the dates indicated: December 31, 2021 2020 Accrued employee bonuses $ 1,254,355 $ 436,799 Payroll and employee benefit accruals 389,385 694,058 Accrued product warranty 97,512 92,696 Other accrued liabilities 281,317 236,325 $ 2,022,569 $ 1,459,878

Debt Obligations (Tables)

Debt Obligations (Tables)	12 Months Ended
	Dec. 31, 2021
Debt Disclosure [Abstract]
Schedule of Current Portion of Long-term Debt, Net	Current portion of long-term debt consisted of the following as of the dates indicated: December 31, 2021 2020 SVB Term Loan $ 5,000,000 $ 2,000,000 PPP Loan — 857,040 2021 Insurance Note 167,586 — 2020 Insurance Note — 165,099 $ 5,167,586 $ 3,022,139
Schedule of Long Term Debt, Net of Current Portion and Discount and Debt Issuance Costs	Long-term debt, net of current portion, discount and debt issuance costs, consisted of the following as of the dates indicated: December 31, 2021 2020 SVB Term Loan, net of discount and debt issuance costs $ 5,178,629 $ 7,708,348 PPP Loan — 859,960 $ 5,178,629 $ 8,568,308
Schedule of Remaining Principal Repayments due Under SVB Term Loan	The remaining principal repayments due under the SVB Term Loan as of December 31, 2021 are as follows for each fiscal year: 2022 $ 5,000,000 2023 5,000,000 Total SVB Term Loan payments 10,000,000 Less discount and deferred financing costs (621,371 ) Plus final fee premium 800,000 Total SVB Term Loan, net $ 10,178,629

Revenue from Contracts with C_2

Revenue from Contracts with Customers (Tables)	12 Months Ended
	Dec. 31, 2021
Revenue From Contract With Customer [Abstract]
Product and Product-Related Service Revenue from Sale of Instruments and Consumables	Product and Product-related Services Revenue The Company had product and product-related services revenue consisting of revenue from the sale of instruments and consumables and the use of the HTG EdgeSeq proprietary technology to process samples and design custom RUO assays for the years ended December 31, 2021 and 2020 as follows: Years Ended December 31, 2021 2020 Product revenue: Instrument $ 1,385,665 $ 869,035 Consumables 3,786,923 3,030,612 Total product revenue 5,172,588 3,899,647 Product-related services revenue: Custom RUO assay design 48,350 1,393,316 RUO sample processing 3,685,890 2,597,891 Total product-related services revenue 3,734,240 3,991,207 Total product and product-related services revenue $ 8,906,828 $ 7,890,854
Schedule of Collaborative Development Services	The Company enters into collaborative development services agreements with biopharmaceutical companies for the development of NGS-based companion diagnostic assays in support of and in conjunction with, biopharmaceutical companies’ drug development programs. These collaborative development services agreements may generate upfront fees, and in some cases subsequent milestone payments that may be earned upon completion of certain product development milestones or activities. The Company follows ASC 606 and ASC 808 to determine the appropriate recognition of revenue under its collaborative research, development and commercialization agreements. For the year ended December 31, 2020, collaborative development services revenue was generated through statements of work entered into under a Master Assay Development, Commercialization and Manufacturing Agreement (the “Governing Agreement”) with QIAGEN Manchester Limited (“QML”) discussed below. Years Ended December 31, 2021 2020 Collaborative development services $ — $ 658,010
Schedule of Changes in Contract Liability	Changes in the Company’s contract liabilities were as follows as of the dates indicated: Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2021 $ 103,580 $ - $ 93,884 $ 197,464 Deferral of revenue 286,349 - 587,091 873,440 Recognition of deferred revenue (261,400 ) - (650,354 ) (911,754 ) Balance at December 31, 2021 $ 128,529 $ — $ 30,621 $ 159,150 Product Revenue Custom RUO Assay Design Sample Processing Total Contract Liability Balance at January 1, 2020 $ 95,148 $ 66,216 $ 438,090 $ 599,454 Deferral of revenue 500,045 566,733 124,404 1,191,182 Recognition of deferred revenue (491,613 ) (632,949 ) (186,888 ) (1,311,450 ) Transfer to refund liability — — (281,722 ) (281,722 ) Balance at December 31, 2020 $ 103,580 $ — $ 93,884 $ 197,464

Other Agreements (Tables)

Other Agreements (Tables)	12 Months Ended
	Dec. 31, 2021
Other Agreements [Abstract]
Schedule of Remaining Minimum Principal Payments Due	Minimum payments to be made in 2022 include $72,624 of revenue-based payments payable as of December 31, 2021 and an estimate of additional revenue-based payments to be made throughout the remainder of 2022 relating to revenue generated in the first, second and third quarters of 2022 using actual revenue generated in the same quarters in 2021. Minimum payments for the remaining years include only the minimum payments for each year. Actual payments could be significantly more than provided in the table, to the extent that 6% of the Company’s annual revenue in those years exceeds $0.4 million: 2022 $ 548,301 2023 400,000 2024 400,000 2025 400,000 2026 400,000 2027 and beyond 2,233,792 Total NuvoGen obligation payments 4,382,093 Plus interest accretion 67,088 Total NuvoGen obligation, net $ 4,449,181

Leases (Tables)

Leases (Tables)	12 Months Ended
	Dec. 31, 2021
Leases [Abstract]
Summary of Components of Lease Cost	The components of lease cost for operating leases were as follows: Years Ended December 31, 2021 2020 Operating leases Operating lease cost $ 503,130 $ 752,413 Variable lease cost 88,708 125,792 Total rent expense $ 591,838 $ 878,205 Years Ended December 31, 2021 2020 Financing leases Amortization of right-of-use assets $ 23,118 $ 42,826 Interest on lease liability 5,793 8,938 Total financing lease cost $ 28,911 $ 51,764
Summary of Other Information Related to Operating Leases	The table below summarizes other information related to the Company’s operating leases: Years Ended December 31, 2021 2020 Cash paid for amounts included in measurement of operating lease liabilities $ 514,453 $ 883,252 Establishment of operating lease liabilities arising from obtaining right-of-use assets $ 1,302,457 $ 447,987 Weighted-average remaining lease term – operating leases 3.1 1.7 Weighted-average discount rate – operating leases 5.8 % 8.0 %
Summary of Remaining Maturities of Operating Leases	As of December 31, 2021, remaining maturities of the Company’s operating leases are as follows: 2022 $ 481,548 2023 484,719 2024 484,631 2025 40,382 Total 1,491,280 Less present value discount (127,954 ) Total operating lease liabilities 1,363,326 Less operating lease liabilities – current (413,865 ) Operating lease liabilities - non-current $ 949,461
Summary of Other Information Related to Financing Leases	The table below summarizes other information related to the Company’s financing leases: Years Ended December 31, 2021 2020 Weighted-average remaining lease term – financing leases 2.8 3.4 Weighted-average discount rate – financing leases 9.77 % 9.77 %
Summary of Remaining Maturities of Financing Leases	As of December 31, 2021, remaining maturities of the Company’s financing leases are as follows: 2022 $ 20,716 2023 18,396 2024 16,080 Total 55,192 Less present value discount (7,081 ) Financing lease liabilities, net $ 48,111

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)	12 Months Ended
	Dec. 31, 2021
Earnings Per Share [Abstract]
Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share	The following table provides a reconciliation of the numerator and denominator used in computing basic and diluted net loss per share for the periods presented: Years Ended December 31, 2021 2020 Numerator: Net loss $ (17,145,170 ) $ (20,870,218 ) Denominator: Weighted-average shares outstanding-basic and diluted * 6,936,131 4,627,918 Net loss per share, basic and diluted $ (2.47 ) $ (4.51 )
Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share	The following common stock equivalents were excluded from the computation of diluted net loss per share for the periods presented because their effect would have been anti-dilutive: Years Ended December 31, 2021 2020 Options to purchase common stock 559,336 487,227 Series A Preferred 158,545 158,545 Common stock warrants 58,688 58,688 Unvested restricted stock units 31,177 12,214

Warrants (Tables)

Warrants (Tables)	12 Months Ended
	Dec. 31, 2021
Proceeds From Issuance Of Preferred Stock Preference Stock And Warrants [Abstract]
Summary of Warrants Outstanding	Warrant Issuance Date Shares of Common Underlying Warrants Exercise Price/Share Expiration Date August 2014 1,914 $ 352.65 2024 December 2014 9,651 210.00 2022 March 2016 3,021 41.40 2026 March 2018 1,208 115.95 2028 June 2020 42,894 11.6565 2030

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2021
Summary of Stock Based Compensation Recognized in Consolidated Statement of Operations	Amounts recognized in the consolidated statements of operations with respect to the Company’s equity incentive plans were as follows: Years Ended December 31, 2021 2020 Selling, general and administrative $ 1,154,000 $ 1,461,190 Research and development 141,281 106,267 Cost of product and product-related services revenue 22,074 17,328 $ 1,317,355 $ 1,584,785
Summary of Stock Option Plans Activity	The following table summarizes stock option activity during the two-year period ended December 31, 2021: Number of Shares Weighted- Average Exercise Price Per Share Weighted- Average Remaining Contractual Life (Years) Aggregate Intrinsic Value Balance at January 1, 2020 193,660 $ 35.55 8.0 $ 781 Granted 387,178 7.81 Exercised - - $ - Forfeited (67,369 ) 12.99 Expired/Cancelled (26,242 ) 32.04 Balance at December 31, 2020 487,227 $ 16.78 8.6 $ 1,536 Granted 153,833 5.45 Exercised (75 ) 4.35 $ 107 Forfeited (52,874 ) 11.98 Expired/Cancelled (28,775 ) 20.39 Balance at December 31, 2021 559,336 $ 13.93 8.2 $ 30,267 Exercisable at December 31, 2020 187,031 $ 27.07 7.5 $ 305 Exercisable at December 31, 2021 298,987 $ 20.14 7.4 $ 6,269
Summary of Material Factors Incorporated in Black-Scholes Model In Estimating Fair Value of Options Granted	The material factors incorporated in the Black-Scholes model in estimating the fair value of the stock options granted for the periods presented were as follows: 2021 2020 Fair value of common stock on grant date $4.07 - 6.25 $4.35 - 11.25 Risk-free interest rate 0.85% - 1.20% 0.34% - 1.65% Expected volatility 104.2% - 107.3% 109.1% - 149.9% Expected term 5.2 to 6.1 years 5.4 to 5.9 years Expected dividend yield 0% 0%
Summary of Restricted Stock Unit (RSU) Plans Activity	The following table summarizes RSU activity during the two-year period ended December 31, 2021: Number of Shares Weighted- Average Grant Date Fair Value Per Share Balance at January 1, 2020 14,916 $ 43.65 Granted 7,000 7.83 Released (7,911 ) 35.85 Forfeited (1,791 ) 41.23 Balance at December 31, 2020 12,214 $ 28.61 Granted 30,000 5.20 Released (4,529 ) 29.13 Forfeited (6,508 ) 24.18 Balance at December 31, 2021 31,177 $ 6.93 Vested and unissued at December 31, 2021 4,148 $ 9.60
Employee Stock Purchase Plan
Summary of Stock Based Compensation Recognized in Consolidated Statement of Operations	Amounts recognized in the consolidated statements of operations with respect to the Amended 2014 ESPP were as follows: Years Ended December 31, 2021 2020 Selling, general and administrative $ 34,219 $ 12,106 Research and development 11,643 5,248 Cost of product and product-related services revenue 11,807 3,832 $ 57,669 $ 21,186
Summary of Material Factors Incorporated in Black-Scholes Model In Estimating Fair Value of Options Granted	The material factors incorporated in the Black-Scholes model in estimating the fair value of employee stock purchase plan stock purchase rights for the periods presented were as follows: 2021 2020 Fair value of common stock $4.67 - 5.85 $8.70 - 9.75 Risk-free interest rate 0.04% - 0.08% 0.18% - 1.58% Expected volatility 71.9% - 89.2% 65.8% - 88.9% Expected term 0.5 years 0.5 years Expected dividend yield 0% 0%
Summary of Shares Purchased under ESPP'S Six Month Purchase Periods	During the year ended December 31, 2021, employees purchased the following shares at the end of each of the six-month purchase periods: June 2021 December 2021 Number of Shares Price per Share Number of Shares Price per Share Total number of shares purchased 13,637 $ 3.92 20,326 $ 3.56 During the year ended December 31, 2020, employees entering the plan at various times throughout the offering period purchased the following shares at the end of each of the six-month purchase periods: June 2020 December 2020 Number of Shares Price per Share Number of Shares Price per Share ESPP Group: Group A 3,033 $ 8.29 2,857 $ 4.87 Group B - N/A 396 4.87 Total number of shares purchased 3,033 3,253

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2021
Commitments And Contingencies Disclosure [Abstract]
Summary of Product Warranty Liability	The following is a summary of the Company’s general product warranty liability. Product warranty liabilities of approximately $97,000 and $23,000 were included in accrued liabilities and other non-current liabilities, respectively, in the accompanying consolidated balance sheets as of December 31, 2021. Expense relating to the recording of this reserve is recorded in cost of product and product-related services revenue within the accompanying consolidated statements of operations. Years Ended December 31, 2021 2020 Beginning balance $ 92,696 $ 94,482 Cost of warranty claims (166,641 ) (32,866 ) Increase in warranty reserve 194,330 31,080 Ending balance $ 120,385 $ 92,696

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2021
Income Tax Disclosure [Abstract]
Summary of Loss Before Income taxes	The following table summarizes loss before income taxes: Years Ended December 31, 2021 2020 U.S. pre-tax loss $ (17,156,070 ) $ (20,855,184 ) Foreign pre-tax gain (loss) 33,375 (619 ) Loss before income taxes $ (17,122,695 ) $ (20,855,803 )
Components of Income Tax Expense	The components of income tax expense are as follows: Years Ended December 31, 2021 2020 Current: Federal $ — $ — State 13,769 10,860 Foreign 8,706 3,555 Total current income tax expense $ 22,475 $ 14,415 Deferred: Federal $ — $ — State — — Foreign — — Total deferred income tax expense $ — $ — Total income tax expense $ 22,475 $ 14,415
Schedule of Difference in Actual Income Tax Expense Computed by Applying the Statutory Federal Income Tax Rate to Loss Before Income Taxes	The Company’s actual income tax expense for the years ended December 31, 2021 and 2020 differ from the expected amount computed by applying the statutory federal income tax rate to loss before income taxes as follows: Years Ended December 31, 2021 2020 Computed tax (benefit) at 21% $ (3,586,925 ) $ (4,379,719 ) State taxes, net of federal benefit (1,177,951 ) (832,055 ) Stock-based compensation 240,177 310,811 Foreign tax rate differential (2,171 ) 3,685 Return to provision 53,340 26,120 Nontaxable loan forgiveness (360,570 ) — Other 9,048 31,850 Research and development tax credit - state (265,362 ) (218,991 ) Research and development tax credit - federal (212,408 ) (197,836 ) Uncertain tax position adjustment for prior periods (6,395 ) (5,694 ) Increase in valuation allowance 5,331,692 5,276,244 $ 22,475 $ 14,415
Schedule of Deferred Tax Assets and Liabilities	Deferred tax assets and liabilities comprise the following: Years Ended December 31, 2021 2020 Deferred tax assets: Net operating loss carryforwards $ 47,752,053 $ 43,308,483 Research and development credits 3,940,199 3,475,341 Deferred revenue 42,802 50,429 Inventory reserve 6,806 6,653 Fixed assets and intangibles 304,019 313,117 Accrued NuvoGen liability 1,196,563 1,274,896 Lease liability 366,653 269,147 Other 711,343 211,574 Gross deferred tax assets 54,320,438 48,909,640 Valuation allowance (53,958,617 ) (48,626,925 ) Deferred tax assets, net 361,821 282,715 Deferred tax liabilities: Right of use asset 361,821 257,705 Other — 25,010 Total deferred tax liabilities 361,821 282,715 Net deferred tax assets (liabilities) $ - $ -
Schedule of Reconciliation of Gross Unrecognized Tax Benefits	A reconciliation of the Company’s gross unrecognized tax benefits is as follows: Years Ended December 31, 2021 2020 Balance at beginning of year $ 2,960,842 $ 2,731,015 Increases to prior positions — — Decreases to prior positions (6,395 ) (5,694 ) Increases for current year positions 238,884 235,521 Balance at end of year $ 3,193,331 $ 2,960,842

Description of Business, Basi_2

Description of Business, Basis of Presentation and Principles of Consolidation - Additional Information (Details)	Nov. 20, 2020	Nov. 30, 2020	Dec. 31, 2021USD ($)Segment	Dec. 31, 2020USD ($)
Significant Accounting Policies [Line Items]
Number of operating segments | Segment			1
Stock split conversion ratio	0.067
Reverse stock split, description			On November 20, 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen (15) shares of issued and outstanding common stock were exchanged for one share of its common stock.
Accumulated deficit			$ (208,333,031)	$ (191,187,861)
Working Capital			17,200,000
Long-term liabilities			10,100,000
Debt instrument, covenant unrestricted cash, including short term available-for-sale securities			$ 12,500,000
SVB Term Loan | Minimum
Significant Accounting Policies [Line Items]
Debt instrument, interest at floating rate			5.00%
Common Stock
Significant Accounting Policies [Line Items]
Stock split conversion ratio		0.15
Reverse stock split, description			In November 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen shares of issued and outstanding common stock were exchanged for one share of common stock.
Sales Revenue, Net | Customer Concentration Risk | Customers Located Outside Of United States
Significant Accounting Policies [Line Items]
Sales revenue percentage			31.00%	35.00%

Summary of Significant Accoun_4

Summary of Significant Accounting Policies - Additional Information (Details)	Apr. 21, 2020USD ($)	May 31, 2021USD ($)	Dec. 31, 2021USD ($)CustomerVendor	Dec. 31, 2020USD ($)CustomerVendor
Significant Accounting Policies [Line Items]
Maturity period of investments			less than one year
Finished goods inventory			$ 447,145	$ 291,195
Impairment of Long-lived assets			0	0
Proceeds from PPP Loan				1,717,000
Gain on forgiveness of PPP Loan			$ 1,735,792
Percentage of qualified wages paid to employees			50.00%
Qualified wages per Employee			$ 10,000
Increased percentage of qualified wages paid to employees			70.00%
Increased qualified wages per Employee			$ 10,000
Employee retention credit benefits			1,708,019	473,483
Employee retention credits benefits receivable			$ 400,000	$ 500,000
ASU 2020-10
Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted			true
Change in accounting principle, accounting standards update, adoption date			Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect			true
ASU 2019-12
Significant Accounting Policies [Line Items]
Change in accounting principle, accounting standards update, adopted			true
Change in accounting principle, accounting standards update, adoption date			Jan. 1, 2021
Change in accounting principle, accounting standards update, immaterial effect			true
Sales Revenue, Net | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer			2
Sales Revenue, Net | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage			20.00%	11.00%
Sales Revenue, Net | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage			10.00%
Accounts Receivable | Customer Concentration Risk
Significant Accounting Policies [Line Items]
Number of customers | Customer			2	2
Accounts Receivable | Customer Concentration Risk | Customer One
Significant Accounting Policies [Line Items]
Sales revenue percentage			18.00%	9.00%
Accounts Receivable | Customer Concentration Risk | Customer Two
Significant Accounting Policies [Line Items]
Sales revenue percentage			17.00%	9.00%
Accounts Receivable | Customer Concentration Risk | Customer Three
Significant Accounting Policies [Line Items]
Sales revenue percentage			10.00%
Accounts Receivable | Customer Concentration Risk | Customer Four
Significant Accounting Policies [Line Items]
Sales revenue percentage			10.00%
Accounts Payable | Supplier Concentration Risk
Significant Accounting Policies [Line Items]
Number of vendors | Vendor			2	2
Accounts Payable | Supplier Concentration Risk | Vendor One
Significant Accounting Policies [Line Items]
Sales revenue percentage			28.00%	21.00%
Accounts Payable | Supplier Concentration Risk | Vendor Two
Significant Accounting Policies [Line Items]
Sales revenue percentage			16.00%	20.00%
U.S. Small Business Administration
Significant Accounting Policies [Line Items]
Gain on forgiveness of PPP Loan		$ 1,735,792
Paycheck Protection Program Loan | Silicon Valley Bank
Significant Accounting Policies [Line Items]
Proceeds from PPP Loan	$ 1,700,000
Software and Software Development Costs
Significant Accounting Policies [Line Items]
Long-term asset, estimated life			3 years
Minimum
Significant Accounting Policies [Line Items]
Period of time customers use to evaluate the Company's equipment			90 days
Long-term asset, estimated life			3 years
Maximum
Significant Accounting Policies [Line Items]
Period of time customers use to evaluate the Company's equipment			180 days
Long-term asset, estimated life			5 years
HTG EdgeSeq
Significant Accounting Policies [Line Items]
Finished goods inventory			$ 204,638	$ 50,855
NuvoGen Asset Purchase Agreement
Significant Accounting Policies [Line Items]
Convertible debt, fair value			$ 4,600,000

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Summary of Related Compensation Costs (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Significant Accounting Policies [Line Items]
Employee retention credit benefits	$ 1,708,019	$ 473,483
Cost of Product and Product-related Services Revenue
Significant Accounting Policies [Line Items]
Employee retention credit benefits	467,481	108,714
Selling, General and Administrative
Significant Accounting Policies [Line Items]
Employee retention credit benefits	795,650	229,025
Research and Development
Significant Accounting Policies [Line Items]
Employee retention credit benefits	$ 444,888	$ 135,744

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Inventory Disclosure [Abstract]
Raw materials	$ 1,964,407	$ 1,079,528
Work in process	312,803	147,455
Finished goods	447,145	291,195
Total gross inventory	2,724,355	1,518,178
Less inventory allowance	(25,306)	(26,052)
Inventory, net	$ 2,699,049	$ 1,492,126

Inventory - Additional Informat

Inventory - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Inventory [Line Items]
Provision for excess inventory	$ 174,589	$ 53,298
Inventory, current	1,987,753	1,492,126
Inventory, noncurrent		$ 0
Inventory Net
Inventory [Line Items]
Inventory, current	2,000,000
Other Noncurrent Assets
Inventory [Line Items]
Inventory, noncurrent	$ 700,000

Fair Value - Financial Assets a

Fair Value - Financial Assets and Liabilities Measured at Fair Value on Recurring Basis (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Asset included in:
Investments available-for-sale at fair value	$ 12,343,456	$ 6,298,075
Corporate Debt Securities
Asset included in:
Investments available-for-sale at fair value	12,343,456	6,298,075
Fair Value, Measurements, Recurring
Asset included in:
Financial Assets	21,426,758	28,294,627
Fair Value, Measurements, Recurring | Money Market Securities
Asset included in:
Cash and cash equivalents	9,083,302	17,497,282
Fair Value, Measurements, Recurring | Corporate Debt Securities
Asset included in:
Cash and cash equivalents		4,499,270
Investments available-for-sale at fair value	12,343,456	6,298,075
Fair Value, Measurements, Recurring | Level 1
Asset included in:
Financial Assets	9,083,302	17,497,282
Fair Value, Measurements, Recurring | Level 1 | Money Market Securities
Asset included in:
Cash and cash equivalents	9,083,302	17,497,282
Fair Value, Measurements, Recurring | Level 2
Asset included in:
Financial Assets	12,343,456	10,797,345
Fair Value, Measurements, Recurring | Level 2 | Corporate Debt Securities
Asset included in:
Cash and cash equivalents		4,499,270
Investments available-for-sale at fair value	$ 12,343,456	$ 6,298,075

Fair Value - Additional Informa

Fair Value - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Fair Value Disclosures [Abstract]
Fair value assets, Level 1 to Level 2 transfers, Amount	$ 0	$ 0
Fair value, assets, Level 2 to Level 1 transfers, Amount	0	0
Fair value, liabilities, Level 1 to Level 2 transfers, Amount	0	0
Fair value, liabilities, Level 2 to Level 1 transfers, Amount	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring basis, asset transfers into Level 3	0	0
Fair value, measurement with unobservable inputs reconciliation, recurring Basis, asset, transfers out of Level 3	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers into Level 3	0	0
Fair Value, measurement with unobservable inputs reconciliation, liability, transfers out of Level 3	$ 0	$ 0

Available-for-Sale Securities -

Available-for-Sale Securities - Summary of Available-for-sale Securities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	$ 12,343,456	$ 6,298,075
Gross Unrealized Losses	0
Fair Value (Net Carrying Amount)	12,343,456	6,298,075
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Amortized Cost	12,343,456	6,298,075
Fair Value (Net Carrying Amount)	$ 12,343,456	$ 6,298,075

Available-for-Sale Securities_2

Available-for-Sale Securities - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Investments Debt And Equity Securities [Abstract]
Available-for-sale securities investments, gross unrealized losses	$ 0
Other-than-temporary impairment	$ 0

Available-for-Sale Securities_3

Available-for-Sale Securities - Summary of Contractual Maturities of Debt Investment Securities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	$ 12,343,456
Fair Value (Net Carrying Amount)	12,343,456	$ 6,298,075
Corporate Debt Securities
Schedule Of Available For Sale Securities [Line Items]
Under 1 Year	12,343,456
Fair Value (Net Carrying Amount)	$ 12,343,456	$ 6,298,075

Property and Equipment - Summar

Property and Equipment - Summary of Property and Equipment (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Furniture & fixtures	$ 872,877	$ 1,082,717
Leasehold improvements	1,931,762	1,943,534
Equipment used in manufacturing	2,432,242	2,166,743
Equipment used in research & development	2,343,930	2,506,644
Equipment used in the field	216,218	208,005
Software	480,740	420,301
Property and equipment	8,277,769	8,327,944
Less: accumulated depreciation and amortization	(7,158,883)	(7,100,542)
Property and equipment, net	$ 1,118,886	$ 1,227,402

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Property Plant And Equipment [Abstract]
Depreciation and leasehold improvement amortization expense	$ 721,246	$ 1,346,560

Accrued Liabilities - Summary o

Accrued Liabilities - Summary of Accrued Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Payables And Accruals [Abstract]
Accrued employee bonuses	$ 1,254,355	$ 436,799
Payroll and employee benefit accruals	389,385	694,058
Accrued product warranty	97,512	92,696
Other accrued liabilities	281,317	236,325
Total accrued liabilities	$ 2,022,569	$ 1,459,878

Debt Obligations - Schedule of

Debt Obligations - Schedule of Current Portion of Long Term Debt, Net (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Current portion of long-term debt, net	$ 5,167,586	$ 3,022,139
SVB Term Loan
Debt Instrument [Line Items]
SVB Term Loan	5,000,000	2,000,000
PPP Loan
Debt Instrument [Line Items]
PPP Loan		857,040
2021 Insurance Note
Debt Instrument [Line Items]
Insurance note	$ 167,586
2020 Insurance Note
Debt Instrument [Line Items]
Insurance note		$ 165,099

Debt Obligations - Schedule o_2

Debt Obligations - Schedule of Long Term Debt, Net of Current Portion and Discount and Debt Issuance Costs (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Long term debt non current	$ 5,178,629	$ 8,568,308
SVB Term Loan
Debt Instrument [Line Items]
Loan, net of discount and debt issuance costs	$ 5,178,629	7,708,348
PPP Loan
Debt Instrument [Line Items]
PPP Loan		$ 859,960

Debt Obligations - Additional I

Debt Obligations - Additional Information (Details) - USD ($)	May 05, 2021	Jun. 25, 2020	Jun. 24, 2020	Apr. 27, 2020	Apr. 21, 2020	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
Loss on extinguishment of MidCap Credit Facility and QNAH Convertible Note							$ (522,394)
Debt instrument, covenant unrestricted cash						$ 12,500,000
Proceeds from Paycheck Protection Program Loan							1,717,000
Gain on forgiveness of PPP Loan						$ 1,735,792
Insurance Note
Debt Instrument [Line Items]
Debt instrument, interest rate	3.57%			3.61%
Debt instrument, maturity date	Jun. 30, 2021			Feb. 28, 2021
Down payment on insurance note	$ 400,000			$ 200,000
Premium payable on insurance note	$ 700,000			$ 700,000
Loan term	9 months			9 months
SVB Term Loan
Debt Instrument [Line Items]
Debt instrument, principal amount		$ 10,000,000
Debt instrument, interest rate			5.75%
Extend the interest-only payments			6 months
Debt instrument, maturity date						Dec. 1, 2023
Debt instrument second anniversary early termination fee percentage			2.00%
Debt instrument after second anniversary early termination fee percentage			1.00%
Debt instrument final payment percentage			8.00%
Warrant to purchase common stock, shares			42,894
Warrant purchase price			$ 11.6565			$ 11.6565
Warrant expiration date			Jun. 24, 2030
Fair value of warrants			$ 400,000
Debt instrument, amortization expense						$ 500,000	200,000
Debt discount, fees and debt issuance costs						$ 621,371	1,100,000
Debt instrument effective interest rate						10.47%
SVB Term Loan | Minimum
Debt Instrument [Line Items]
Debt instrument, interest at floating rate						5.00%
SVB Term Loan | Prime Rate | Minimum
Debt Instrument [Line Items]
Debt instrument, interest at floating rate			2.50%
Paycheck Protection Program Loan
Debt Instrument [Line Items]
Debt instrument, interest rate					1.00%
Paycheck Protection Program Loan | SBA
Debt Instrument [Line Items]
Accrued liability with risk of adverse review						$ 0
Paycheck Protection Program Loan | Other Income (Expense)
Debt Instrument [Line Items]
Gain on forgiveness of PPP Loan						$ 1,700,000
Paycheck Protection Program Loan | Silicon Valley Bank
Debt Instrument [Line Items]
Proceeds from Paycheck Protection Program Loan					$ 1,700,000
QIAGEN North American Holdings, Inc. | Convertible Promissory Note
Debt Instrument [Line Items]
Repayments of aggregate amount		3,200,000
MidCap Credit Facility
Debt Instrument [Line Items]
Repayment of outstanding principal and interest		$ 7,500,000
MidCap Credit Facility | QIAGEN North American Holdings, Inc.
Debt Instrument [Line Items]
Loss on extinguishment of MidCap Credit Facility and QNAH Convertible Note							$ 500,000

Debt Obligations - Schedule o_3

Debt Obligations - Schedule of Remaining Principal Repayments due Under SVB Term Loan (Details) - SVB Term Loan - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Debt Instrument [Line Items]
2022	$ 5,000,000
2023	5,000,000
Total SVB Term Loan payments	10,000,000
Less discount and deferred financing costs	(621,371)	$ (1,100,000)
Plus final fee premium	800,000
Total SVB Term Loan, net	$ 10,178,629

Revenue from Contracts with C_3

Revenue from Contracts with Customers - Product and Product-Related Service Revenue from Sale of Instruments and Consumables (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	$ 8,906,828	$ 8,548,864
Product and Product-related Services
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	8,906,828	7,890,854
HTG EdgeSeq | Instruments
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	1,385,665	869,035
HTG EdgeSeq | Consumables
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	3,786,923	3,030,612
HTG EdgeSeq | Product revenue
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	5,172,588	3,899,647
HTG EdgeSeq | Custom RUO assay design
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	48,350	1,393,316
HTG EdgeSeq | RUO Sample processing
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	3,685,890	2,597,891
HTG EdgeSeq | Product-related services revenue
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	3,734,240	3,991,207
HTG EdgeSeq | Product and Product-related Services
Disaggregation Of Revenue [Line Items]
Product and product-related services revenue	$ 8,906,828	$ 7,890,854

Revenue from Contracts with C_4

Revenue from Contracts with Customers - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Agreements for product and product-related services revenue, description	the Company’s agreements for product and product-related services revenue have an expected duration of one year or less
Contract liabilities – current	$ 124,941	$ 185,083
Custom RUO Assay Design and Related Agreements
Disaggregation Of Revenue [Line Items]
Revenue recognized	$ 0	$ 0
Minimum
Disaggregation Of Revenue [Line Items]
Customer payment term	30 days
Maximum
Disaggregation Of Revenue [Line Items]
Customer payment term	90 days

Revenue from Contracts with C_5

Revenue from Contracts with Customers - Additional Information1 (Details)	Dec. 31, 2021
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date: 2022-01-01
Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year

Revenue from Contracts with C_6

Revenue from Contracts with Customers - Schedule of Collaborative Development Services (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Service revenue	$ 8,906,828	$ 8,548,864
Collaborative Development Services
Disaggregation Of Revenue [Line Items]
Service revenue		$ 658,010

Revenue from Contracts with C_7

Revenue from Contracts with Customers - Schedule of Changes in Contract Liability (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Disaggregation Of Revenue [Line Items]
Beginning Balance	$ 197,464	$ 599,454
Deferral of revenue	873,440	1,191,182
Recognition of deferred revenue	(911,754)	(1,311,450)
Transfer to refund liability		(281,722)
Ending Balance	159,150	197,464
Product Revenue
Disaggregation Of Revenue [Line Items]
Beginning Balance	103,580	95,148
Deferral of revenue	286,349	500,045
Recognition of deferred revenue	(261,400)	(491,613)
Ending Balance	128,529	103,580
Custom RUO Assay Design
Disaggregation Of Revenue [Line Items]
Beginning Balance		66,216
Deferral of revenue		566,733
Recognition of deferred revenue		(632,949)
Sample Processing
Disaggregation Of Revenue [Line Items]
Beginning Balance	93,884	438,090
Deferral of revenue	587,091	124,404
Recognition of deferred revenue	(650,354)	(186,888)
Transfer to refund liability		(281,722)
Ending Balance	$ 30,621	$ 93,884

Other Agreements - Additional I

Other Agreements - Additional Information (Details)	12 Months Ended
	Dec. 31, 2021USD ($)	Dec. 31, 2020USD ($)
Other Agreements [Line Items]
Asset purchase agreement aggregate cash compensation paid	$ 15,000,000
Accretion expense	$ (12,288)	$ (12,936)
Measurement Input, Default Rate
Other Agreements [Line Items]
Discount rate used to calculate asset purchase obligation	2.5
NuvoGen Asset Purchase Agreement
Other Agreements [Line Items]
Percentage on annual revenues for cash consideration to be paid	6.00%
Asset purchase agreement yearly fixed fees paid	$ 400,000	400,000
Asset purchase agreement fixed quarterly payments	$ 100,000	200,000
Percentage of compounded annual interest on unpaid Obligation	2.50%
Additional revenue based payments payable	$ 72,624
NuvoGen
Other Agreements [Line Items]
Unamortized interest accretion	(67,088)	(79,376)
Accretion expense	$ (12,288)	$ (12,935)

Other Agreements - Schedule of

Other Agreements - Schedule of Remaining Minimum Principal Payments Due (Details) - NuvoGen Asset Purchase Agreement	Dec. 31, 2021USD ($)
Purchase Obligation Fiscal Year Maturity [Line Items]
2022	$ 548,301
2023	400,000
2024	400,000
2025	400,000
2026	400,000
2027 and beyond	2,233,792
Total NuvoGen obligation payments	4,382,093
Plus interest accretion	67,088
Total NuvoGen obligation, net	$ 4,449,181

Leases - Additional Information

Leases - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Lessee Lease Description [Line Items]
Operating lease, description	The Company’s active leases as of December 31, 2021 relate to the Company’s office and manufacturing space in Tucson, Arizona, and expire in 2025.
Lease expiration year	2025
Operating lease right-of-use assets	$ 1,345,361	$ 1,009,097
Financing lease liabilities, net of discount	48,111
Financing lease liabilities, current	$ 16,807
Finance Lease, Liability, Current, Statement of Financial Position [Extensible List]	Other current liabilities
Financing lease liabilities, non current	$ 31,304
Finance Lease, Liability, Noncurrent, Statement of Financial Position [Extensible List]	Other non-current liabilities
Financing leases, right-of-use assets	$ 43,651
Finance Lease, Right-of-Use Asset, Statement of Financial Position [Extensible Enumeration]	Property and equipment, net
Tucson, Arizona
Lessee Lease Description [Line Items]
Extended lease term	The Company amended its Tucson facility leases in December 2020 to extend the terms of the leases for one year, through January 31, 2022 and again in September 2021 to extend the terms of the leases for three years, through January 31, 2025. The lease extensions were treated as lease modifications for accounting purposes, and allow for an additional extension of two years on the same terms and conditions
San Carlos, California | Research and Development
Lessee Lease Description [Line Items]
Operating lease right-of-use assets	$ 200,000

Leases - Summary of Components

Leases - Summary of Components of Lease Cost for Operating Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Operating lease cost	$ 503,130	$ 752,413
Variable lease cost	88,708	125,792
Total rent expense	$ 591,838	$ 878,205

Leases - Summary of Other Infor

Leases - Summary of Other Information Related to Operating Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Cash paid for amounts included in measurement of operating lease liabilities	$ 514,453	$ 883,252
Establishment of operating lease liabilities arising from obtaining right-of-use assets	$ 1,302,457	$ 447,987
Weighted-average remaining lease term – operating leases	3 years 1 month 6 days	1 year 8 months 12 days
Weighted-average discount rate – operating leases	5.80%	8.00%

Leases - Summary of Remaining M

Leases - Summary of Remaining Maturities of Operating Leases (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
2022	$ 481,548
2023	484,719
2024	484,631
2025	40,382
Total	1,491,280
Less present value discount	(127,954)
Total operating lease liabilities	1,363,326
Less operating lease liabilities – current	(413,865)	$ (685,220)
Operating lease liabilities - non-current	$ 949,461	$ 368,682

Leases - Summary of Component_2

Leases - Summary of Components of Lease Cost for Financing Leases (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Amortization of right-of-use assets	$ 23,118	$ 42,826
Interest on lease liability	5,793	8,938
Total financing lease cost	$ 28,911	$ 51,764

Leases - Summary of Other Inf_2

Leases - Summary of Other Information Related to Financing Leases (Details)	Dec. 31, 2021	Dec. 31, 2020
Leases [Abstract]
Weighted-average remaining lease term – financing leases	2 years 9 months 18 days	3 years 4 months 24 days
Weighted-average discount rate – financing leases	9.77%	9.77%

Leases - Summary of Remaining_2

Leases - Summary of Remaining Maturities of Financing Leases (Details)	Dec. 31, 2021USD ($)
Leases [Abstract]
2022	$ 20,716
2023	18,396
2024	16,080
Total	55,192
Less present value discount	(7,081)
Financing lease liabilities, net	$ 48,111

Net Loss per Share - Reconcilia

Net Loss per Share - Reconciliation of Numerator and Denominator Used in Computing Basic and Diluted Net Loss per Share (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Numerator:
Net loss	$ (17,145,170)	$ (20,870,218)
Denominator:
Weighted-average shares outstanding-basic and diluted	6,936,131	4,627,918
Net loss per share, basic and diluted	$ (2.47)	$ (4.51)

Net Loss per Share - Common Sto

Net Loss per Share - Common Stock Equivalents Excluded from Computation of Diluted Net Loss per Share (Details) - shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Options to purchase common stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	559,336	487,227
Warrants | Common Stock
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	58,688	58,688
Unvested Restricted Stock Units
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	31,177	12,214
Series A Preferred
Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]
Anti-dilutive securities excluded from computation of diluted net loss per share	158,545	158,545

Warrants - Additional Informati

Warrants - Additional Information (Details) - USD ($)	1 Months Ended	12 Months Ended
	Mar. 31, 2020	Dec. 31, 2021	Dec. 31, 2020	Jun. 30, 2021	Jun. 24, 2020	Sep. 30, 2019
Class Of Warrant Or Right [Line Items]
Proceeds from exercise of pre-funded warrants			$ 31,768
SVB Term Loan
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants					42,894
Exercise price of warrants		$ 11.6565			$ 11.6565
Warrant to purchase common stock		42,894
Warrant purchase price		$ 11.6565			$ 11.6565
Warrant expire date		Jun. 24, 2030
Minimum | SVB Term Loan
Class Of Warrant Or Right [Line Items]
Warrant to purchase common stock		42,894
Common Stock
Class Of Warrant Or Right [Line Items]
Number of shares issued upon the conversion		144,881	183,333
Private Placement | Institutional Accredited Investors
Class Of Warrant Or Right [Line Items]
Exercise price of warrants						$ 9.75
Warrant purchase price						$ 9.75
Private Placement | Institutional Accredited Investors | Pre-funded Warrants
Class Of Warrant Or Right [Line Items]
Number of securities called by warrants						360,779
Exercise price of warrants						$ 9.60
Exercise price of warrants, exercisable subject to beneficial ownership limitations						0.15
Warrants exercised	211,784			148,995
Proceeds from exercise of pre-funded warrants	$ 31,768
Warrant purchase price						$ 9.60

Warrants -Summary of Warrants O

Warrants -Summary of Warrants Outstanding (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Jun. 24, 2020
Series E Redeemable Convertible Preferred Stock
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2014-08
Shares of Common Stock Underlying Warrants	1,914
Exercise price of warrants	$ 352.65
Expiration Date	2024
Convertible Note Warrants
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2014-12
Shares of Common Stock Underlying Warrants	9,651
Exercise price of warrants	$ 210
Expiration Date	2022
Common Stock Warrants
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2016-03
Shares of Common Stock Underlying Warrants	3,021
Exercise price of warrants	$ 41.40
Expiration Date	2026
Common Stock Tranche one
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2018-03
Shares of Common Stock Underlying Warrants	1,208
Exercise price of warrants	$ 115.95
Expiration Date	2028
SVB Term Loan
Class Of Warrant Or Right [Line Items]
Warrant Issuance Date	2020-06
Shares of Common Stock Underlying Warrants	42,894
Exercise price of warrants	$ 11.6565	$ 11.6565
Expiration Date	2030

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details)

Nov. 20, 2020$ / sharesshares

Mar. 24, 2020USD ($)$ / sharesshares

Feb. 25, 2020USD ($)$ / sharesshares

Nov. 30, 2019$ / shares

Nov. 30, 2020

Dec. 31, 2021USD ($)$ / sharesshares

Dec. 31, 2020USD ($)$ / sharesshares

Dec. 31, 2019shares

Dec. 31, 2015shares

Aug. 31, 2021shares

Jul. 31, 2021shares

Aug. 31, 2020shares

Sep. 30, 2019$ / sharesshares

Class Of Stock [Line Items]

Reverse stock split, description

On November 20, 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen (15) shares of issued and outstanding common stock were exchanged for one share of its common stock.

Stock split conversion ratio

0.067

Common stock split Price per share | $ / shares

$ 4.27

Fractional shares from reverse stock split share

0

Common stock, shares outstanding

7,588,085

5,199,997

Common stock, shares issued

7,588,085

5,199,997

Common stock, shares authorized

26,666,667

26,666,667

Common stock, par value | $ / shares

$ 0.001

$ 0.001

Preferred stock, shares authorized

10,000,000

Preferred stock, par value | $ / shares

$ 0.001

Weighted-average fair value of stock options granted | $ / shares

$ 4.38

$ 6.40

Maximum aggregate number of common stock available purchase under employee stock purchase plan

16,666

Maximum number of shares that may be purchased by eligible participants under employee stock purchase plan

500

Stock issued under employee stock purchase plans

0

0

Employee Stock Option

Class Of Stock [Line Items]

Stock option granted

153,833

387,178

Unrecognized compensation expense | $

$ 1,300,000

Compensation expense period expected to be recognized

2 years 6 months 7 days

Options to purchase common stock outstanding

559,336

487,227

193,660

Restricted Stock Units R S U

Class Of Stock [Line Items]

Unrecognized compensation expense | $

$ 200,000

Compensation expense period expected to be recognized

1 year 5 months 19 days

Weighted-average fair value of RSUs granted | $ / shares

$ 5.20

$ 7.83

Vested and unissued RSU awards, description

Vested and unissued awards at December 31, 2021 represents RSU awards granted in August 2018 and November 2021 for which a portion of the awards vested on December 31, 2021, but for which issuance of shares occurred in  January 2022.

Vested and unissued RSU awards granted date

Aug. 31, 2018

Vested and unissued RSU awards vesting date

Dec. 31, 2021

Vested and unissued RSU awards issuance date

Jan. 31, 2022

Restricted Stock Units R S U | Share-based Payment Arrangement, Tranche One

Class Of Stock [Line Items]

Vested and unissued RSU awards granted date

Nov. 30, 2021

2020 Equity Incentive Plan

Class Of Stock [Line Items]

Shares reserved for issuance

744,685

Number of shares available for issuance

558,865

2014 Equity Incentive Plan

Class Of Stock [Line Items]

Shares reserved for issuance

68,552

Number of shares available for issuance

0

Options granted in term

10 years

2021 Inducement Plan

Class Of Stock [Line Items]

Shares reserved for issuance

300,000

Number of shares available for issuance

160,000

2021 Inducement Plan | Restricted Stock Units R S U

Class Of Stock [Line Items]

Stock option granted

30,000

0

Inducement Awards | Employee Stock Option

Class Of Stock [Line Items]

Stock option granted

110,000

0

Amended and Restated 2014 Employee Stock Purchase Plan

Class Of Stock [Line Items]

Shares reserved for issuance

500,000

2014 Employee Stock Purchase Plan

Class Of Stock [Line Items]

Shares reserved for issuance

24,285

Maximum | 2014 Equity Incentive Plan | Board Of Directors

Class Of Stock [Line Items]

Options exercise period

4 years

Minimum | 2014 Equity Incentive Plan | Board Of Directors

Class Of Stock [Line Items]

Options exercise period

1 year

Common Stock

Class Of Stock [Line Items]

Reverse stock split, description

In November 2020, the Company completed a reverse stock split of its outstanding shares of common stock pursuant to which every fifteen shares of issued and outstanding common stock were exchanged for one share of common stock.

Stock split conversion ratio

0.15

Number of shares issued upon the conversion

144,881

183,333

Stock issued under employee stock purchase plans

33,963

6,286

Cantor Sales Agreement

Class Of Stock [Line Items]

Common stock price per share | $ / shares

$ 0.001

Percentage of commission aggregate gross proceeds from each sale of shares

3.00%

Exchange Agreement

Class Of Stock [Line Items]

Common stock, shares outstanding

274,000

Conversion of convertible preferred stock into common stock

6.67

Exchange Agreement | Common Stock

Class Of Stock [Line Items]

Number of shares issued upon the conversion

27,500

Exchange Agreement | Series A Convertible Preferred Stock

Class Of Stock [Line Items]

Issuance of common stock, shares

10,170

Preferred stock, shares issued

41,100

Preferred stock, par value | $ / shares

$ 0.001

Issuance of common stock | $

$ 600,000

Stock issued, price per share | $ / shares

$ 59

Preferred stock, shares converted

183,333

Preferred stock, shares outstanding

23,770

L P Purchase Agreement

Class Of Stock [Line Items]

Issuance of common stock | $

$ 899,980

L P Purchase Agreement | Common Stock

Class Of Stock [Line Items]

Issuance of common stock, shares

154,372

Issuance of common stock | $

$ 154

Lincoln Park | L P Purchase Agreement

Class Of Stock [Line Items]

Common stock price per share | $ / shares

$ 5.2155

Net proceeds from issuance of common stock from the ATM Offering | $

$ 900,000

$ 1,000,000

Common stock value right to sell, maximum | $

$ 20,000,000

Agreement term

36 months

Minimum purchase amount extent to sell shares | $

$ 150,000

Maximum amount of any single business day's purchase shares

166,666

Percentage of common stock outstanding

19.99%

Percentage of beneficially owing common stock

9.99%

Common stock, shares issued

41,026

154,372

197,632

Common stock weighted average price per share | $ / shares

$ 5.83

$ 4.94

Lincoln Park | L P Purchase Agreement | Maximum

Class Of Stock [Line Items]

Number of common stock may sell in regular purchase on single business day

20,000

Lincoln Park | L P Purchase Agreement | Maximum | Closing Price of Common Stock is Not Below $7.50

Class Of Stock [Line Items]

Increased number of common stock may sell in regular purchase on single business day

23,333

Lincoln Park | L P Purchase Agreement | Maximum | Closing Price of Common Stock is Not Below $11.25

Class Of Stock [Line Items]

Increased number of common stock may sell in regular purchase on single business day

26,666

Lincoln Park | L P Purchase Agreement | Minimum

Class Of Stock [Line Items]

Closing stock price | $ / shares

$ 1.50

Lincoln Park | L P Purchase Agreement | Minimum | Closing Price of Common Stock is Not Below $7.50

Class Of Stock [Line Items]

Closing stock price of common stock | $ / shares

7.50

Lincoln Park | L P Purchase Agreement | Minimum | Closing Price of Common Stock is Not Below $11.25

Class Of Stock [Line Items]

Closing stock price of common stock | $ / shares

$ 11.25

Private Placement | Institutional Accredited Investors

Class Of Stock [Line Items]

Exercise price of warrants | $ / shares

$ 9.75

Private Placement | Institutional Accredited Investors | Pre-funded Warrants

Class Of Stock [Line Items]

Number of securities called by warrants

360,779

Exercise price of warrants | $ / shares

$ 9.60

Exercise price of warrants, exercisable subject to beneficial ownership limitations | $ / shares

$ 0.15

ATM Offering

Class Of Stock [Line Items]

Gross proceeds from issuance of common stock | $

$ 11,000,000

$ 7,900,000

Payment of sales commissions | $

300,000

200,000

Net proceeds from issuance of common stock from the ATM Offering | $

10,700,000

7,500,000

Issuance of common stock | $

$ 10,665,819

$ 7,545,838

ATM Offering | Common Stock

Class Of Stock [Line Items]

Issuance of common stock, shares

2,050,879

955,240

Deferred offering costs | $

$ 100,000

Issuance of common stock | $

$ 2,051

$ 955

ATM Offering | Common Stock

Class Of Stock [Line Items]

Issuance of common stock, shares

2,050,879

Employee Stock Purchase Plan

Class Of Stock [Line Items]

Shares reserved for issuance

503,959

Number of shares available for issuance

11,658

Vested and unissued RSU awards, description

Under the 2014 ESPP, the number of shares of common stock reserved for issuance automatically increased on January 1 of each calendar year, from January 1, 2016 to January 1, 2021 by the lesser of (i) 1% of the total number of shares of the Company’s common stock outstanding on December 31 of the preceding calendar year, (ii) 13,000 shares, or (iii) a number determined by the Company’s Board of Directors that is less than (i) and (ii).

Common stock issuance offering date

Jan. 1, 2016

Common stock issuance expiration date

Jan. 1, 2021

Percentage of common stock outstanding

1.00%

Options to purchase common stock outstanding

13,000

Maximum contribution eligible compensation during a period to purchase common stock

15.00%

Fair market value of company common stock, shares offering price

85.00%

Fair market value of company common stock, shares purchase price

85.00%

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Stock Based Compensation Recognized in Consolidated Statement of Operations (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 1,317,355	$ 1,584,785
Amended 2014 ESPP
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	57,669	21,186
Selling, General and Administrative
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	1,154,000	1,461,190
Selling, General and Administrative | Amended 2014 ESPP
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	34,219	12,106
Research and Development
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	141,281	106,267
Research and Development | Amended 2014 ESPP
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	11,643	5,248
Cost of Product and Product-related Services Revenue
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	22,074	17,328
Cost of Product and Product-related Services Revenue | Amended 2014 ESPP
Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]
Stock-based compensation	$ 11,807	$ 3,832

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Stock Option Plans Activity (Details) - Employee Stock Option - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning Balance	487,227	193,660
Number of Shares, Granted	153,833	387,178
Number of Shares, Exercised	(75)
Number of Shares, Forfeited	(52,874)	(67,369)
Number of Shares, Expired/Cancelled	(28,775)	(26,242)
Number of Shares, Ending Balance	559,336	487,227	193,660
Number of Shares, Exercisable	298,987	187,031
Weighted-Average Exercise Price Per Share, Beginning Balance	$ 16.78	$ 35.55
Weighted-Average Exercise Price Per Share, Granted	5.45	7.81
Weighted-Average Exercise Price Per Share, Exercised	4.35
Weighted-Average Exercise Price Per Share, Forfeited	11.98	12.99
Weighted-Average Exercise Price Per Share, Expired/Cancelled	20.39	32.04
Weighted-Average Exercise Price Per Share, Ending Balance	13.93	16.78	$ 35.55
Weighted-Average Exercise Price Per Share, Exercisable	$ 20.14	$ 27.07
Weighted-Average Remaining Contractual Life, Outstanding	8 years 2 months 12 days	8 years 7 months 6 days	8 years
Weighted-Average Remaining Contractual Life, Exercisable	7 years 4 months 24 days	7 years 6 months
Aggregate Intrinsic Value, Balance	$ 1,536	$ 781
Aggregate Intrinsic Value, Exercised	107
Aggregate Intrinsic Value, Balance	30,267	1,536	$ 781
Aggregate Intrinsic Value, Exercisable	$ 6,269	$ 305

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Material Factors Incorporated in Black-Scholes Model in Estimating Fair Value of Options Granted (Details) - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	0.85%	0.34%
Risk-free interest rate, maximum	1.20%	1.65%
Expected volatility, minimum	104.20%	109.10%
Expected volatility, maximum	107.30%	149.90%
Expected dividend yield	0.00%	0.00%
Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Risk-free interest rate, minimum	0.04%	0.18%
Risk-free interest rate, maximum	0.08%	1.58%
Expected volatility, minimum	71.90%	65.80%
Expected volatility, maximum	89.20%	88.90%
Expected term	6 months	6 months
Expected dividend yield	0.00%	0.00%
Minimum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	5 years 2 months 12 days	5 years 4 months 24 days
Minimum | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock on grant date	$ 4.07	$ 4.35
Minimum | Common Stock | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock on grant date	$ 4.67	$ 8.70
Maximum
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected term	6 years 1 month 6 days	5 years 10 months 24 days
Maximum | Common Stock
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock on grant date	$ 6.25	$ 11.25
Maximum | Common Stock | Employee Stock Purchase Plan
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Fair value of common stock on grant date	$ 5.85	$ 9.75

Stockholders' Equity - Summar_4

Stockholders' Equity - Summary of Material Factors Incorporated in Black-Scholes Model in Estimating Fair Value of Options Granted (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2021USD ($)
Class Of Stock [Line Items]
Expected dividend assumed value	$ 0
2014 Employee Stock Purchase Plan
Class Of Stock [Line Items]
Expected dividend assumed value	$ 0

Stockholders' Equity - Summar_5

Stockholders' Equity - Summary of RSU Award Activity (Details) - Restricted Stock Units R S U - $ / shares	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Restricted Stock Units (RSU)
Beginning Balance	12,214	14,916
Granted	30,000	7,000
Released	(4,529)	(7,911)
Forfeited	(6,508)	(1,791)
Ending Balance	31,177	12,214
Vested and unissued at December 31, 2021	4,148
Weighted Average Grant Date Fair Value Per Share
Beginning Balance	$ 28.61	$ 43.65
Granted	5.20	7.83
Released	29.13	35.85
Ending Balance	6.93	28.61
Forfeited	24.18	41.23
Vested and unissued at December 31, 2021	9.60
Forfeited	$ 24.18	$ 41.23

Stockholders' Equity - Summar_6

Stockholders' Equity - Summary of Shares Purchased under ESPP'S Six Month Purchase Periods (Details) - $ / shares	6 Months Ended
	Dec. 31, 2021	Jun. 30, 2021	Dec. 31, 2020	Jun. 30, 2020
Class Of Stock [Line Items]
Number of Shares	20,326	13,637	3,253	3,033
Price per Share	$ 3.56	$ 3.92
2014 Employee Stock Purchase Plan Group A
Class Of Stock [Line Items]
Number of Shares			2,857	3,033
Price per Share			$ 4.87	$ 8.29
2014 Employee Stock Purchase Plan Group B
Class Of Stock [Line Items]
Number of Shares			396
Price per Share			$ 4.87

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Product Warranty Liability [Line Items]
Accrued product warranty	$ 97,512	$ 92,696
Discretionary contributions company may make	0	$ 0
Accrued Liabilities
Product Warranty Liability [Line Items]
Accrued product warranty	97,000
Other Non-Current Liabilities
Product Warranty Liability [Line Items]
Product warrant liabilities	$ 23,000

Commitments and Contingencies_2

Commitments and Contingencies - Summary of Product Warranty Liability (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Commitments And Contingencies Disclosure [Abstract]
Beginning balance	$ 92,696	$ 94,482
Cost of warranty claims	(166,641)	(32,866)
Increase in warranty reserve	194,330	31,080
Ending balance	$ 120,385	$ 92,696

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020	Dec. 31, 2019
Income Tax Disclosure [Line Items]
Income tax examination, likelihood of unfavorable settlement	greater than 50 percent
Uncertain tax positions	$ 3,200,000	$ 3,000,000
Accrued interest or penalties	0	0
Recognized interest or penalties	0	0
Valuation allowance	53,958,617	48,626,925
Change in valuation reserve	$ 5,300,000
Period for cumulative change in ownership	3 years
Gross unrecognized tax benefits	$ 3,193,331	$ 2,960,842	$ 2,731,015
Unrecognized tax benefits if recognized would impact effective tax rate	$ 0
CARES Act of 2020 percentage of NOL carryovers and carrybacks offsetting taxable income	100.00%
Research and Experimental Tax Credits
Income Tax Disclosure [Line Items]
Gross unrecognized tax benefits	$ 3,200,000
Minimum
Income Tax Disclosure [Line Items]
Cumulative changes in ownership percentage	50.00%
Federal
Income Tax Disclosure [Line Items]
NOL carryforwards	$ 194,000,000
State
Income Tax Disclosure [Line Items]
NOL carryforwards	125,600,000
With Expiration | Federal
Income Tax Disclosure [Line Items]
NOL carryforwards	121,800,000
With Expiration | State
Income Tax Disclosure [Line Items]
NOL carryforwards	$ 124,600,000
Beginning Expiration Year | Federal
Income Tax Disclosure [Line Items]
NOL carryforward expiration year	2023
Tax credit carryforward, expiration year	2022
Beginning Expiration Year | State
Income Tax Disclosure [Line Items]
NOL carryforward expiration year	2024
Tax credit carryforward, expiration year	2022
Ending Expiration Year | Federal
Income Tax Disclosure [Line Items]
NOL carryforward expiration year	2037
Ending Expiration Year | State
Income Tax Disclosure [Line Items]
NOL carryforward expiration year	2041

Income Taxes - Summary of Loss

Income Taxes - Summary of Loss Before Income taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
U.S. pre-tax loss	$ (17,156,070)	$ (20,855,184)
Foreign pre-tax gain (loss)	33,375	(619)
Net loss before income taxes	$ (17,122,695)	$ (20,855,803)

Income Taxes - Components of In

Income Taxes - Components of Income Tax Expense (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Current:
State	$ 13,769	$ 10,860
Foreign	8,706	3,555
Total current income tax expense	22,475	14,415
Total income tax expense	$ 22,475	$ 14,415

Income Taxes - Difference in Ac

Income Taxes - Difference in Actual Income Tax Expense Computed by Applying the Statutory Federal Income Tax Rate to Loss Before Income Taxes (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Line Items]
Computed tax (benefit) at 21%	$ (3,586,925)	$ (4,379,719)
State taxes, net of federal benefit	(1,177,951)	(832,055)
Stock-based compensation	240,177	310,811
Foreign tax rate differential	(2,171)	3,685
Return to provision	53,340	26,120
Nontaxable loan forgiveness	(360,570)
Other	9,048	31,850
Uncertain tax position adjustment for prior periods	(6,395)	(5,694)
Increase in valuation allowance	5,331,692	5,276,244
Total income tax expense	22,475	14,415
State
Income Tax Disclosure [Line Items]
Research and development tax credit	(265,362)	(218,991)
Federal
Income Tax Disclosure [Line Items]
Research and development tax credit	$ (212,408)	$ (197,836)

Income Taxes - Difference in _2

Income Taxes - Difference in Actual Income Tax Expense Computed by Applying the Statutory Federal Income Tax Rate to Loss Before Income Taxes (Parenthetical) (Details)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Statutory federal income tax rate	21.00%	21.00%

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Tax Assets and Liabilities (Details) - USD ($)	Dec. 31, 2021	Dec. 31, 2020
Deferred tax assets:
Net operating loss carryforwards	$ 47,752,053	$ 43,308,483
Research and development credits	3,940,199	3,475,341
Deferred revenue	42,802	50,429
Inventory reserve	6,806	6,653
Fixed assets and intangibles	304,019	313,117
Lease liability	366,653	269,147
Other	711,343	211,574
Gross deferred tax assets	54,320,438	48,909,640
Valuation allowance	(53,958,617)	(48,626,925)
Deferred tax assets, net	361,821	282,715
Deferred tax liabilities:
Right of use asset	361,821	257,705
Other		25,010
Total deferred tax liabilities	361,821	282,715
NuvoGen
Deferred tax assets:
Accrued liability	$ 1,196,563	$ 1,274,896

Income Taxes - Schedule of Reco

Income Taxes - Schedule of Reconciliation of Gross Unrecognized Tax Benefits (Details) - USD ($)	12 Months Ended
	Dec. 31, 2021	Dec. 31, 2020
Income Tax Disclosure [Abstract]
Balance at beginning of year	$ 2,960,842	$ 2,731,015
Decreases to prior positions	(6,395)	(5,694)
Increases for current year positions	238,884	235,521
Balance at end of year	$ 3,193,331	$ 2,960,842

Subsequent Events - Additional

Subsequent Events - Additional Information (Details) - Subsequent Event - March 2022 Purchase Agreement $ / shares in Units, $ in Millions	Mar. 21, 2022USD ($)$ / sharesshares
Subsequent Event [Line Items]
Exercise price of warrants	$ 2.062
Warrant issuance, description	Each unit consisted of one share of common stock (or one pre-funded warrant in lieu thereof), a common warrant to purchase one share of the Company’s common stock with a term of 24 months from the issuance date, and a common warrant to purchase one share of the Company’s common stock with a term of 66 months from the issuance date.
Pre-funded Warrants
Subsequent Event [Line Items]
Exercise price of warrants	$ 0.001
Investor
Subsequent Event [Line Items]
Number of securities called by warrants | shares	3,244,987
Exercise price of warrants	$ 2.312
Gross proceeds from issuance of warrants | $	$ 7.5
Investor | Pre-funded Warrants | Maximum
Subsequent Event [Line Items]
Exercise price of warrants	$ 0.001